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ABSTRACT 
Acute kidney injury and chronic kidney disease are becoming more prevalent and have 
high morbidity and mortality, and despite several therapies targeted towards treating or 
preventing kidney injury, outcomes have been unchanged for many years. Calcium-
independent phospholipase A2y (iPLA2y) is one of seven Ca
2
+ -independent PLA2 
enzymes and represents a potential therapeutic target in kidney disease because of its 
unique subcellular localization and its potential as the putative membrane 
remodeling/repair enzyme. Studies in our laboratory suggest iPLA2Y is cytoprotective 
during oxidant injury by preventing and/or repairing oxidant-induced lipid peroxidation 
and pointed to ER- iPLA2Y as the major component of membrane repair and remodeling. 
The goals of these studies are to understand the role of ER- iPLA2y in oxidant-induced 
ER lipid peroxidation, Ca2+ release, loss of lipid homeostasis, and renal cell death. Our 
studies in isolated microsomes (ER) provide evidence that inhibition of ER-
iPLA2¥ results in the potentiation of oxidant-induced lipid peroxidation. Studies in renal 
proximal tubule cells confirmed that iPLA2¥ is protective of oxidant-induced lipid 
peroxidation and genetic ablation of iPLA2¥ in mice resulted in oxidant injury (lipid 
peroxidatioh and mitochondrial DNA damage). To determine the role of ER- iPLA2¥ in 
oxidant-induced Ca2+ release we developed assays to measure ER Ca2+ release from 
IV 
isolated microsomes and in RPTC uSIng Ca2+ -sensitive fluorophores. These studies 
showed ER- iPLA21 prevented oxidant-induced ER Ca
2
+ release. 
To determine the role of iPLA21 in oxidant-induced loss of lipid homeostasis, we 
employed electron spray ionization-mass spectrometry (ESI-MS) to measure lipid 
changes (phospholipids and fatty acids) in isolated micro somes, RPTC, and 
iPLAtt KO mouse urine. These studies provide evidence that ER- iPLA2Y mediates 
oxidant-induced fatty acid release (oxidized and/or unsaturated) in isolated microsomes; 
iPLA2y inhibition results in the build-up several phospholipids within renal cell 
membranes; and genetic ablation of iPLA2y in mIce results In decreased 
phosphatidylcholine containing phospholipids and increased fatty acids with methyl or 
keto additions (likely lipid hydroperoxides) in mouse urine. 
Our studies in RPTC demonstrated ER- iPLA21 protects renal cell from oxidant-induced 
necrotic cell death by preventing ER membrane disruption and subsequent Ca2+ release. 
We report the first in vivo studies suggesting that genetic ablation of iPLA2Y results in 
kidney oxidant injury, induces compensatory mitochondrial changes and upregulation of 
antioxidant stress pathways, however does not result measurable loss of kidney function. 
Together these data support our previous findings that iPLA21 is cytoprotective in renal 
cells and provide evidence that iPLA2y is critical for the prevention and/or repair of lipid 
peroxidation in oxidative kidney injury. 
v 
Chapter 1 
Review of Acute Renal Failure and Phospholipase A2 Biology 
Kidney Function and Dysfunction. The kidneys are involved many functions including 
water and electrolyte balance, regulation of arterial blood pressure, regulation of blood 
cell synthesis, vitamin D production and fasting-induced gluconeogenesis [1]. The 
kidneys are also responsible for the removal of water soluble waste products, such as 
blood urea nitrogen (BUN) and creatinine, and xenobiotics, such as cisplatin and 
aminoglycosides. Impaired kidney function, resulting in loss of electrolyte and water 
balance and the build up of these compounds, results in neurological disturbances (ie 
delirium, coma, and seizure), cardiac arrhythmias, fatigue, edema, and hypertension. 
Complications from loss of kidney function result in significant morbidity and mortality. 
Acute Kidney Injury. Acute kidney injury (AKI), in the clinical setting, is generally 
diagnosed based upon an abrupt increase in serum creatinine (SCr) within the setting of 
clinical symptoms such as nausea, vomiting, fatigue, and/or edema. This syndrome was 
once termed acute renal failure until a more strict and accurate definition was adopted. 
AKI requires a greater than 0.3 mg/dl (425 mmolll) rise or a > 50% increase in serum 
creatinine, oliguria (a reduction in urine output <0.5 mllkg/h for greater than 6 h, or an 
acute palliative need for dialysis [2]. The most recent criteria for defining the severity of 
AKI stratifies the stages of injury from a minor insult causing minimal damage to 
significant injury resulting in End-Stage Renal Disease (ESRD) [3]. These criteria are 
termed RIFLE (Risk, Injury, Failure, Loss, and ESRD) and were developed because the 
1 





Crl GFR Criteria 
Increased Cr x1.S 
or 
GFR decreases >250/0 
Increased Cr x 2 
or 
GFR decreases >500/0 
Increased Cr x 3 
or 
Urine Output (UO) Criteria 
UO <0.5 mllkg/hr 
x 6 hr 
UO <0.5 mllkg/hr 
x 12 hr 
UO <0.3 mVkg/hr 
x24 hr 
Failure 




Cr~ 4 mg/dl 
(with acute rise 
of;Z; 0.5 mg/dl) 
anuria x 12 hr 
Persistent ARF = 
complete loss of renal function 
for> 4 weeks 
End Stage Renal 
Disease 
Figure 1-1. The RIFLE classification. The RIFLE criteria stratifies the stage of insult 
from minor to major resulting in ESRD. The shape of the figure reflects the incidence of 
patients within each stage. Importantly, more patients will be included in the mild 
category while the bottom criteria are more strict and therefore more specific. GFR, 
glomerular filtration rate; ARF, acute renal failure, ESRD, end stage renal disease. From 
Bellomo et al [3]. 
2 
AKI Morbidity and Mortality. AKI is associated with significant morbidity and 
mortality. Epidemiological studies revealed that most AKI cases occur in hospitalized 
patients and more specifically, patients in intensive care unit (ICU) [5]. ICU patients 
with AKI are associated with as high as 90% mortality rates, presumably due to the 
presence co-morbidities, including liverlheart failure and sepsis [6]. Although AKI is 
associated with co-morbidities and the presence of other diseases may influence mortality 
rates, AKI is independently associated with increased mortality in epidemiological 
studies that adjust for the contribution of co-mobidities [7]. The mortality rate in 
uncomplicated AKI is estimated to be as high as 23%. Mortality rates range from 10-
80% depending on the population studied (from uncomplicated AKI to those patients 
requiring renal replacement therapy) [8-9]. 
Reliable statistics on incidence, cost, and mortality associated with AKI are hard to assess 
because the numbers are inherently dependent on the population studied and incidence is 
often tied with other disease states. However, retrospective studies from in-patient 
hospital records estimate the incidence rate to be approximately 5-7% (approximately 1 % 
community-acquired), and this number increases to approximately 20% in critically-ill 
patients [10] A more useful and likely more appropriate assessment of the contribution 
of AKI to poor health outcomes would be to quantify the added mortality, length of stay 
and cost attributed to hospital-acquired AKI. One study examining the data by 
incremental changes in serum creatinine, found that even a moderate change in serum 
creatinine (0.3 - 0.4 mg/dl) resulted in a 70% increase in risk of death, a 3.5 day increase 
in length of stay, and a $9000 increase in health care associated costs [11]. These 
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numbers were greatly increased when considering more robust changes In serum 
creatinine (0.5 - 2.0 mg! dl increases). 
AKI and Chronic Kidney Disease. Recent studies suggest AKI contributes to incident 
and prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD). 
Approximately 10-40 million adults have CKD and over one half million were treated for 
ESRD via dialysis or kidney transplantation in the US in 2007 [12]. The number of 
patient with ESRD is projected to increase to 0.8 million by 2020. Additionally, there 
has been a considerable increase in the incidence of AKI, which appears to be related to 
the increased number of invasive medical and surgical procedures in the management of 
critically ill elderly patients. In summary, AKI is responsible for significant increases in 
morbidity, mortality, health care costs, and length of stay of both hospitalized/critically-
ill patients and in patients presenting with AKI as a primary diagnosis. 
Treatments for AKI. Clinical treatment options for AKI are limited to supportive 
measures including maintenance of intravascular volume, blood pressure regulation, 
immediate discontinuation of suspected nephrotoxic drugs and correction of electrolyte 
abnormalities [2]. Hyperkalemia is a common consequence of AKI, which can lead to 
life threatening arrhythmias. Potassium binding resins, fluid maintenance, and dietary 
restriction are first line treatments for hyperkalemia associated with AKI [2]. 
Unfortunately, dialysis and kidney transplant have remained the gold standard of care for 
the treatment of AKI for over 40 years and there has been no improvement in health 
outcomes. Continuous renal replacement therapy (CRRT) and intermittent hemodialysis 
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cost approximately $4000/week and $1000/week, respectively while kidney transplant 
carries with it it's own risks and co-morbidities such as the necessary immunosuppression 
and related complications [13]. Several new agents have been proposed for the treatment 
of AKI and target the many components contributing to kidney injury. Unfortunately, 
while these treatment approaches seem promising in the laboratory setting, none have 
contributed significantly to outcomes in clinical trials (Figure 1-2) [14]. 
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Figure 1-2 Proposed Treatment Strategies for AKI. Many therapeutics have been 
developed but none have resulted in significant improvement in clinical outcomes. 
Adapted from Kinsey and Okusa, 2011 [14]. 
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Causes of AKI There are three major causes of AKI or ARF, classified as prerenal, 
intrarenal and postrenal. Prerenal ARF is characterized by decreased blood flow to the 
kidney secondary to decreased intravascular volume (ie. dehydration from excessive 
diuresis, vomiting, and/or diarrhea) or decreased blood flow (ie. renal artery stenosis, 
liver and heart failure, and shock associated loss of intravascular pressure) [2]. The 
widely used medications, non-steroidal anti-inflammatory drugs (NSAIDs) and 
angiotensin-converting enzyme inhibitors (ACEIs) can cause prerenal ARF by decreasing 
the pressure in Bowman's capsule. NSAIDs block the production of vasodilatory 
prostaglandins and drive the production of thromboxane A2 causing the vasoconstriction 
of afferent arterioles resulting in decreased blood flow into the capsule in the absence of 
compensatory changes within the efferent arterioles leading to decreasing glomerular 
pressure and glomerular filtration rate (GFR). ACEIs decrease levels of angiotensin II 
resulting in dilation of efferent arterioles in the absence of increased blood flow into the 
glomerulus through the afferent arterioles resulting in a similar drop in glomerular 
pressure and GFR [15]. Pre-renal failure accounts for 40-70% of all renal failure and is 
primarily observed in the community setting and upon admission into the hospital [16]. 
Clinically, pre-renal failure may be diagnosed by measuring urine and serum electrolytes 
and creatinine and calculating the Fractional Excretion of Sodium (FENA). A FENA 
value of less that 1 % is suggestive of a pre-renal component of kidney dysfunction. 
Post-renal ARF can be identified by an obstruction of urine outflow from the kidneys. 
Obstruction may be caused by anatomical obstruction (developmental abnormalities, 
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strictures, benign prostatic hypertrophy, abdominal aortic aneurysms, or tumors) or 
physical obstruction (ie. kidney stones, cellular debris or catheters) [17]. The extent of 
damage to the kidney and therefore risk of end stage renal disease is proportional to the 
extent of obstruction and the length of time the obstruction is present [2]. Anatomical 
malformations, hyperkalemia, and other metabolic disturbances are common sequelae of 
post-renal obstruction and should be monitored closely and treated promptly. 
Intra-renal ARF is a result of dysfunction within the kidney and is divided into 4 groups 
characterized by the anatomical region most significantly affected (glomerular, 
interstitial, vascular and tubular). Intrarenal ARF is sometimes used interchangeably 
with acute tubular necrosis (A TN), although necrosis does not seem to be the only 
underlying mechanism of cell death. Intrarenal ARF is the most common cause of 
kidney failure in the hospital setting [2]. 
Glomerular causes of ARF are relatively uncommon and are often associated with 
immunological disorders such as systemic lupus erythematosus, Goodpasture's disease, 
and other nephritic/nephrotic disorders. Systemic findings such as fever, arthritis and 
rash are commonly present in patients with glomerular ARF [2]. Interstitial ARF is less 
well understood, but is often caused by infection, autoimmune diseases or allergic 
reaction to several drugs (ie. allopurinol; cephalosporins; ciprofloxacin; NSAIDs; 
penicillins; sulfonamides and thiazide diuretics) [2]. Vascular ARF results from renal 
artery stenosis or occlusion of smaller vessels inside the kidney. Because of the apparent 
overlap in the causes of ARF and their classification, grouping is becoming less relevant, 
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but the mechanism of injury has become more important to understanding the etiology of 
the disease. 
Acute Tubular Necrosis. Although ATN is often used interchangeably with intra-renal 
failure, necrosis is often not the only and sometimes not the major mechanism of cell 
death. However, ATN is characterized by injury to and death of tubular epithelial cells. 
Histological findings associated with A TN include: loss of brush border, thinning of the 
tubular epithelial cell layer, interstitial edema, sloughing of cells into the lumen of the 
tubule and tubular dilation (Figure 1-3) [18]. ATN is most commonly caused by 
ischemia, ischemiaireperfusion, anoxia, or drug and toxicant injury. 
8 
Figure 1-3. Representative histology (hematoxin and eosin stain) of a normal kidney 
and of a kidney exhibiting acute tubular necrosis. i. Normal kidney cortex 
morphology. Ischemialreperfusion-induced acute tubular necrosis at 24 h (ii), 72 h (iii), 
or 144 h (iv) after ischemia-reperfusion injury at 40X magnification. Morphology 
consistent with acute tubular necrosis including tubular dilation, loss of brush border and 
increased space between tubules. From Funk and Schnellmann, 2011 [19]. 
nephrotoxic drugs or chemicals [20-21]. Proximal tubule cells are especially sensitive to 
insult because of their high energy demand secondary to their extensive ATP-dependent 
transport capacity. Renal proximal tubule cells lack the capability of producing 
glycolytic ATP during periods of ischemia [22]. Several drugs selectively target RPTC 
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because, in the process of transporting nephrotoxic drugs into and out of the urIne, 
intracellular concentrations of these drugs reach high levels. Aminoglycoside antibiotics 
and anticancer drugs such as cisplatin are examples of agents that are directly toxic to 
RPTC and induce ARF. Mercury and cadmium are examples of environmental toxins that 
can induce cell death ofRPTC and precipitate ARF [23]. 
There are 3 stages of ATN termed: initiation, maintenance and recovery. Initiation is the 
time immediately following toxicant exposure or ischemia and GFR is severely reduced. 
The maintenance phase can last up to 2 weeks and is associated with a continued 
reduction in GFR, decreased urine output and increased BUN and SCr. The kidney has 
restorative and regenerative capacities very similar to the liver that enable them to restore 
function following A TN if the initiating insult is not overwhelming. The recovery phase 
is characterized by increased urine output, increased GFR, and a decline in SCr and BUN. 
Interestingly, most patients who survive A TN recover full renal function with little 
evidence of dead tubular tissue, demonstrating the regenerative capacity of the kidney 
[21]. 
RPTC Cell Death in ATN. Epithelial cell death can occur via necrosis and/or apoptosis 
and both are involved in the pathophysiology of A TN [24]. A TP levels during and 
following injury is a major determinant of the type of cell death that ensues [25]. 
Sufficient A TP levels are required to initiate and execute apoptosis and apoptosis is 
generally considered an ATP dependent process. For example, an insult that depletes 
10 
ATP levels acutely in a cell to 15% or less will induce necrotic cell death, while cell 
injury with less A TP depletion usually results in apoptosis [25]. Apoptosis and necrosis 
have significant different effects on surrounding cells and tissues and these differences 
may be very important in the progression of many disease processes. Apoptosis, the 
more organized form of cell death, is thought to protect surrounding tissues from non-
specific proteolytic degradation while signaling to neighboring injured cells to carry out 
the same process. It is also important to note that some types of cell death display 
combinations of necrotic and apoptotic characteristics [26]. 
Necrosis. Necrosis is characterized by loss of plasma membrane integrity and release of 
intracellular contents. The intracellular contents themselves contain activated proteolytic 
enzymes which damage neighboring cells while resulting in the robust activation of 
immune cells which can lead to inflammation and further disruption of neighboring 
tissues [27]. Rapid ATP depletion is a major trigger of necrotic cell death in the kidney. 
ATP depletion impairs ion transporters, especially the Na+/K+-ATPase and Ca2+-ATPase, 
leading to increased cytosolic concentrations of Na+ and Ca2+ [28]. The increased 
cytosolic N a + has two major impacts that facilitate the progression of necrotic cell death. 
Initially, the Na+ drives the osmotic movement of water into the cell causing swelling. 
Additionally, the intracellular Na+ inhibits the Na+/Ca2+ exchanger leading to further 
increased cytosolic Ca2+, which has several deleterious effects on the cell. Ca2+ activates 
cytosolic calpains, mediating the loss of cell membrane integrity by cleaving cytoskeletal 
proteins which support the plasma membrane [29]. Increased cytosolic Ca2+ is also 
buffered by active mitochondria. Ca2+ sequestration promotes the opening of a 
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proteinaceous pore called the mitochondrial permeability transition (MPT) pore, leading 
to further ATP deph:~tion [30]. Late in necrotic cell death, cr and water influx facilitate 
opening of a glycine-sensitive plasma membrane pore, the "death channel", which is 
porous to macromolecules up to 145 kDa, leads to membrane rupture [31-32]. 
Apoptosis. Apoptosis is a major contributor to cell death following ischemic and toxic 
insults [20, 24]. Apoptosis is an ATP-dependent process that is highly regulated and 
involves several signaling pathways that results in the organized cell death. During 
apoptosis, cells maintain plasma membrane integrity and results in cell shrinkage rather 
than swelling (swelling is a characteristic finding of necrotic cell death). Extemalization 
of phosphatidylserine in the setting of preserved plasma membrane integrity signals 
phagocytic cells such as macrophages to migrate towards and engulf injured cells 
undergoing apoptotic cell death. The apoptosis may be initiated by both extracellular 
stimuli and intracellular signals. Interestingly, while rapid and severe A TP depletion is a 
hallmark of necrotic cell death, GTP (guanosine triphosphate) depletion is a major trigger 
for apoptotic cell death in the kidney [33]. 
Extracellular-mediated (extrinsic) apoptosis IS initiated by the binding of signaling 
ligands to receptors on the plasma membrane, which results in the activation of very 
organized signaling cascades. For example, tumor necrosis factor (TNF)-related 
apoptosis-inducing ligand (TRAIL), Fas, and TNF receptor 1 (TNFR1) ligand binding 
results in receptor aggregation on the plasma membrane, initiating the formation of the 
death-inducing signaling complex (DISC) The DISC is comprised of activated and 
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aggregated receptors, the Fas-associated death domain (F ADD), and procaspase 8 and its 
formation results in procaspase 8 cleavage to caspase 8. Caspases are a family of 
cysteine proteases that play a role in the initation and execution of apoptotic cell death. 
Caspase 8 directly cleaves and activates procaspses 3, 6, and 7 (executioner caspases). In 
the proximal tubule, death receptors are expressed and up-regulated after injury [34] 
representing one mechanism of RPTC apoptosis during ARF. Additionally, mice 
lacking TNFRI exhibit less apoptotic cell death and decreased kidney dysfunction 
following a toxic insult. 
Opening of the mitochondrial permeability transition (MPT) pore [30] or 
permeablization of the outer mitochondrial membrane by members of the BCL-2 family 
or other mechanisms [35] releases cytochrome c and other factors that facilitate 
apoptosis. When cytochrome c is released from the mitochondria it interacts with Apaf-l 
and procaspase-9 to form the apoptosome. The apoptosome, if A TP is present, activates 
caspase-9 which cleaves and activates procaspase-3. Permeablization of the outer 
mitochondrial membrane also releases Smac/Diablo, Endonuclease G and apoptosis 
inducing factor (AIF). Smac/Diablo releases causes apoptosis by inhibiting inhibitor of 
apoptosis proteins (lAPs). lAPs prevent caspase cleavage and activation [36]. 
Endonuclease G and AIF participate in DNA degradation associated with apoptosis [36]. 
Interestingly, the kidneys of mice lacking cyclophillin D, a critical component of the 
MPT pore, are protected from ischemia-reperfusion injury. Additionally, proapoptotic 
members of the BCL-2 family including BID and BAX translocate to mitochondria and 
form pores leading to release of apoptotic mediators in models of AKI, while 
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overexpression of antiapototic members such as BCL-xL prevents the release of these 
mediators, prevents apoptosis, and preserves kidney function following kidney injury. 
ROS. Reactive oxygen species are a major component of many disease processes and 
mediate injury and response to injury during ATN [20-21]. ROS is the byproduct of 
several cellular processes (ie. the incomplete reduction of O2 in mitochondria, 
inflammatory cell activation, and drug and toxicant metabolism) [20]. Superoxide and 
hydrogen peroxide (H20 2) are important oxidant molecules that are produced by 
mitochondria under normal conditions and in greater quantities upon reperfusion or in 
mitochondria damaged by toxicants [37]. Increased cytosolic Ca2+ also leads to 
superoxide production by activation of proteases which cleave xanthine dehydrogenase to 
yield xanthine oxidase [38]. Superoxide dismutase is a major intracellular antioxidant 
enzyme that metabolizes superoxide to H202. H20 2 can then be reduced to water by 
catalase or it can be converted to the damaging HO' radical in the presence of ferrous iron 
(Fe2+) or cuprous ions. HO' radicals are produced in the kidney shortly after reperfusion 
in experimental models of ARF [39-40]. Finally, peroxynitrite, produced from the 
reaction of superoxide with nitrous oxide, is also reported to contribute to the pathology 
associated with ischemic ARF [41]. 
ROS damage cellular proteins, DNA and lipids. Protein oxidation is elevated after 
ischemia and reperfusion in the rat kidney and the increase is blocked by the antioxidant 
n-acetylcysteine [38]. ROS, especially H202 are implicated in DNA strand breaks which 
can induce cells to undergo apoptosis [20]. Lipid peroxidation describes the chain 
14 
reaction initiated when a free radical abstracts hydrogen from an unsaturated fatty acid 
linked to a phospholipid inside a cellular membrane. If it is not stopped, lipid 
peroxidation can potentially destroy an organelle or cell membrane. Lipid peroxidation 
of cell and organelle membranes increases membrane rigidity and permeability to ions 
[20-21]. Furthermore, ROS-mediated lipid oxidation in the mitochondrial inner 
membrane inhibits the function of the electron transport chain [42]. End products of lipid 
peroxidation such as 4-hydroxy-2,3-nonenal have biological actions including increasing 
passive Ca2+ permeability in biological membranes [43]. In summary~ ROS damage 
various intracellular targets and lipid peroxidation inhibits membrane structure and 
function, impairs mitochondrial function and leads to Ca2+ influx. 
Ca2+ Regulation. Ca2+ acts as a universal second messenger and regulates numerous 
cellular functions including metabolism, motility, and transport [ 44]. Loss of Ca2+ 
homeostasis is critical to many disease processes and is a major component of cell death 
pathways including necrosis, apoptosis, and autophagy [45-51] (Figure 1-4). 
Sarcoplasmic/endoplasmic reticulum (ER) Ca2+ is the most abundant store of intracellular 
Ca2+ and its disruption often initiates the deleterious cascade of events leading to cell 
death and dysfunction [48-54]. Release of the ER Ca2+ stores is a key trigger for necrotic 
cell death in renal cells [53]. Thapsigargin inhibits the ER Ca2+-ATPase (SERCA) 
causing release of ER Ca2+ and in the presence of A TP the cell can pump out the excess 
cytosolic Ca2+, effectively depleting the ER Ca2+ store. Harriman et al. (2002) showed 
that thapsigargin exposure prior to A TP depletion blocked calpain activation and necrotic 
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cell death, establishing the importance of this intracellular pool of Ca2+ in the death of 


















Figure 1-4. Schematic of the role of Ca2+ in renal cell death. 1. Cytosolic Ca2+ is 
regulated by numerous mechanisms and organelles inside renal cells. 2. Endoplasmic 
reticulum Ca2+ -ATPase (SERCA) pumps on the ER membrane pump Ca2+ into the lumen 
of the ER to buffer cytosolic levels participate in signaling. 3. During injury cytosolic 
Ca2+ concentrations exceed 400-500 nM and mitochondria begin to actively sequester 
Ca2+. This causes opening of the mitochondrial permeability transition (MPT) pore 
leading to mitochondrial swelling and inhibition of A TP synthesis. Mitochondrial 
swelling facilitates the release of cytochrome c ( cyt c), apoptosis inducing factor (AIF), 
smac/diablo from the intermembrane space of mitochondria which in the presence of 
ATP cause the cell to undergo apoptosis. If MPT has spread to a sufficient proportion of 
mitochondria and cellular A TP becomes depleted the cell will undergo necrosis. 4. A 
rise in cytosolic Ca2+ also activates cytosolic calpain, a protease which mediates 
apoptosis and necrosis. 5. Membrane bound Ca2+ efflux pumps use the Na+ gradient and 
A TP to remove Ca2+ from the cytosol. 6. Ca2+ enters from the extracellular space 
through a voltage gated channel. Adopted with permission from Kinsey OR 2007. 
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Mitochondria have a large capacity for Ca2+, which is shuttled into the matrix by a 
ruthenium red (RR)-sensitive channel called the Ca2+ uniporter [55]. In the kidney, 
substantial mitochondrial Ca2+ uptake occurs after cytosolic concentrations reach 400 nM 
or greater which is usually only seen during cell injury [56]. There is a negative 
correlation between the matrix Ca2+ concentration and oxidative phosphorylation and 
A TP production [21]. Furthermore, mitochondrial Ca2+ accumulation favors the opening 
of the MPT pore, which depolarizes the inner membrane and compounds the injury with 
futile ATP hydrolysis by F(l )F(O)-ATP synthase in reverse mode in an attempt to restore 
mitochondrial membrane potential [57]. In summary, Ca2+ is an important signal from 
the ER and to the mitochondria during renal cell death. 
Role of Phospholipase A2 in AKI. Phospholipase A2 (PLA2) activity has been 
implicated in the progression of ischemialreperfusion-induced failure of the heart, brain, 
and kidney. Ischemia has been shown to activate PLA2 leading to membrane 
degradation and lysophospholipid accumulation, which impair membrane function and 
integrity and lead to cell death [58-61]. Additionally, secretory and Ca2+ -dependent 
phospholipase A2 inhibitors prevented cell death in vivo after heart [62] and brain [63] 
ischemialreperfusion (I/R). The addition of purified bee or snake venom secretory PLA2 
to hypoxic rat renal proximal tubules caused degradation of phospholipids which 
increased as ATP levels declined and was mitigated by addition of ATP [64]. While cell 
death was not measured, PLA2 addition inhibited uncoupled respiration and decreased 
intracellular K+ content during hypoxia [64]. Cytosolic Ca2+ -independent PLA2 (iPLA2) 
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is reportedly activated by hypoxia in rabbit renal proximal tubule sections, while no 
change was observed in membrane-bound iPLA2 activity in this model during hypoxia 
[65]. Inhibition of cytosolic iPLA2 activity inhibited hypoxia-induced arachidonic acid 
generation and lactate dehydrogenase release [65]. In summary, many studies have 
implicated PLA2-mediated membrane degradation in the cell injury induced by I/R in 
several organs including the kidney. 
However, in different studies, addition of pancreatic PLA2 or venom PLA2 to hypoxic rat 
renal proximal tubule segments prevented cell death even in the presence of A TP 
depletion [66-67]. The protective effect of PLA2 in these studies is hypothesized to be 
due to a negative feedback effect of unsaturated free fatty acids on endogenous PLA2 
[21]. Additionally, studies from our laboratory have shown that membrane-associated 
iPLA2 inhibition in primary cultures of rabbit RPTC potentiates oxidant-induced lipid 
peroxidation and necrosis [68]. In summary, the different isoforms of PLA2 may have 
different roles in ARF and the role of iPLA2 in ARF may depend on its intracellular 
localization. 
Phospholipids. The major structural components of cell and organelle membranes are 
phospholipids (PLs). There are hundreds of different types of phospholipids in 
mammalian membranes which can vary in the fatty acids linked at the sn-l and sn-2 
positions, the type of linkage between the glycerol backbone and the sn-l fatty acid, and 
the polar head group [69] (Figure 1-5). In addition to providing a barrier between the 
extra- and intracellular space, PLs playa vital role in cell signaling. For example, 
stimulation of G-protein coupled receptors (GPCRs) activates phospholipase C (PLC) 
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which cleaves the PL phosphatidylinositol-4,5-bisphosphate in the cell membrane, 
generating inositol-triphosphate and diacylglycerol (DAG). These two molecules play 
key roles in the intracellular signaling of GPCR activation by triggering the release of ER 
Ca2+ and activating PKC, respectively. PLs are precursors of platelet activating factor 
(PAF) that interacts with a GPCR to regulate cardiac function and renal blood flow and 
may mediate atherogenesis [70-71]. In summary, phospholipids are a class of molecules 
with an extremely large number of members, are required as a major structural 
component of cell and organelle membranes and are used to transmit signals inside the 
cell and from one cell to another. 
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Figure 1-5. Glycerophospholipids and site of PLA2 hydrolysis. PLA2 enzymes 
catalyze the cleavage of the sn-2 ester bond of glycerophospholipids (*). Fatty acids of 
14 to 24 carbons in length, containing 0 to 6 double bonds are esterified to the glycerol 
backbone at the sn-2 position. At the sn-1 position, fatty acids can be linked to the 
glycerol backbone by an ester bond (shown) and referred to as a phosphatidyl- or diacyl-
phospholipid or by a vinyl ether bond and referred to as a plasmenyl- phospholipid. 
Phospholipids with an ether linkage at the sn-1 are termed plasmanyl- phospholipids. 
Fatty acids. Phospholipids are a reservoir of fatty acids, the structural building blocks of 
phospholipids and another very important component of cell signaling. Arachidonic acid 
(AA, a fatty acid with 20 carbons and 4 double bonds, denoted 20:4) is the most well 
known and extensively studied fatty acid although many other fatty acids have biological 
activity. AA is metabolized by: cyclooxygenases to prostaglandins and thromboxane A2; 
lipoxygenases to leukotrienes and cytochrome p450 enzymes to several other oxidized 
signaling molecules [72]. Other fatty acids, such as linoleic, oleic, and palmitic acids are 
20 
in high abundance in the kidney and are thought to play a major role in phospholipid 
structure and function and cell signaling (Figure 1-6) [73]. 
# of Trivial Name Systematic Weight 
Carbons: Name Percentage in 
Double Kidney* 
Bonds 
14:0 Myristic tetradecanoic <1 
15:0 n.a. pentadecanoic <1 
16:0 Palmitic hexadecanoic 19.2 
16: 1 Palmitoleic hexadecenoic 2.4 
17:0 Margaric heptadecanoic <1 
18:0 Stearic octadecanoic 13.4 
18:1 Oleic octadecaenoic 21.9 
18:2 Linoleic octadecadienoic 24.4 




20:4 Arachidonic eicosatetraenoic 12.1 
20:5 n.a. eicosapentaenoic <1 
22:5 n.a. docosapentaenoic 1.7 
22:6 n.a. docosahexaenoic <1 
Figure 1-6. Common fatty acid components of mammalian kidney phospholipids. 
*Mean weight percentage of each fatty acid in lipids of kidney from D. C. Rule et aI., 
1994 [73]. Most abundant fatty acids are in bold. n.a. - fatty acids without established 
trivial names. 
Lipid Peroxidation. ROS generation is a major component of ischemialreperfusion and 
drug and toxicant injury. Major targets of ROS are cell and organelle membrane 
phospholipids [74]. The initiation step of lipid peroxidation involves the abstraction of a 
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hydrogen atom from the methylene carbon of a fatty acid and therefore fatty acids with 
more double bonds are more vulnerable to the initiation of lipid peroxidation [75]. These 
fatty acid species are usually polyunsaturated fatty acids (PUF As). Abstraction of the 
hydrogen atom from PUF As forms a pentadienyl radical, which in aerobic conditions 
reacts with oxygen to form a peroxyl radical. The resulting peroxyl radical is capable of 
abstracting a hydrogen atom from adjacent fatty acids, thus propagating the lipid 
peroxidation and potentially producing several lipid hydroperoxides [76]. This chain of 
events can be terminated by the removal of the reactive lipid from the site of reaction or a 
chain-breaking antioxidant (Figure 1-7) [75-77]. 
22 
°2 
ems,c.-: ., c~··W\W,:·<- ~'.' '-"'X' r )f""~'-'---'-u . "--mew I b -. :':':""'-'(wt7 wn'" ': '. 1 "-- ~, :'w'" ~ 'tt ' 
A. 






Figure 1-7. Schematic representation of free radical attack on membrane 
phospholipids. (A) Initiation of lipid peroxidation. The free radical (X', normally a 
hydroxyl radical) abstracts a proton from an sn-2 unsaturated fatty acid linked to the 
glycerol backbone of a membrane phospholipid, forming a pentadienyl radical (a). 
Oxygenation forms a peroxyl radical and a conjugated diene, (b). (B) Propagation of lipid 
peroxidation. The peroxyl radical abstracts a proton from a methylene of a neighboring 
polyunsaturated fatty acid forming a new pentadienyl radical that react with oxygen to 
form another peroxyl radical and this pattern continues until the oxidized fatty acids are 
removed from the membrane or react with a chain terminating molecule such as u-
tocpherol. Adapted from [78-79] 
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In mammalian tissues, PUF As are predominantly esterified at the sn-2 position of PLs 
[80]. It has been proposed that phospholipases playa role in membrane remodeling and 
repair during oxidant stress by cleaving oxidized and/or unsaturated fatty acids from the 
membrane, preventing the initiation and propagation of lipid peroxidation, and allowing 
for the incorporation of unoxidized fatty acids [74]. ER and mitochondria are the major 
sites of reactive oxygen species (ROS) production and the presence of iPLA2y in 
mitochondria and ER of rabbit RPTC makes it a likely candidate for a role in membrane 
repair and remodeling. The most probable mechanism by which these enzymes prevent 
or repair lipid peroxidation is through the cleavage and removal of oxidized fatty acids 
from the membrane [81] The liberated oxidized free fatty acid can then be reduced by 
cytosolic glutathione peroxidase (GPx) and the lysophospholipid reacylated by a CoA-
dependent acyltransferase to reform a non-oxidized phospholipid and preserve membrane 
integrity [82]. In vitro analyses in non-cell based systems have demonstrated that, in 
concert with GPx, PLA2 enzymes are capable of performing this protective repair 
function [83-85]. Thus far, the PLA2 isoform(s) involved in this important cell survival 
function has not been determined in vivo or in an intact cell model. However, recent 
studies from our laboratory have demonstrated that inhibition of membrane-associated 
iPLA2 activity in RPTC potentiated oxidant-induced lipid peroxidation [68], but thus far 
the tools necessary to identify this isoform have not been available. Furthermore, the role 
of this lipid peroxidation repair pathway in prevention of or hastening recovery from 
ARF has not been addressed. 
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Review of Phospholipase A2 Biology 
PLA2 Overview. Phospholipase A2 (PLA2) enzymes catalyze the hydrolysis of fatty 
acids at the sn-2 position of glycerophospholipids resulting in the production of a free 
fatty acid and a lysophospholipid [86]. Free fatty acids and their metabolites are 
biologically active in such processes as inflammation, cell signaling, and cell death. 
Interestingly, Polyunsaturaed fatty acids (PUFAs) are predominately esterified at the sn-2 
position of phospholipids [80]. Arachidonic acid, for example, is metabolized to 
prostaglandins, prostacyclins, thromboxanes and leukotrienes, all of which playa role in 
inflammatory responses and cell signaling [87]. The resulting lysophospholipids serve as 
substrates for the re-esterification of free fatty acids by eoA-dependent acyltransferases 
and are also cell signaling molecules [82]. The deacylation and reacylation of 
phospholipids is termed "The Lands Cycle" and may be involved in membrane 
remodeling and the maintenance of membrane homeostasis under physiological and 
pathological conditions. However, there are limited studies investigating this 
phenomenon in cellular systems [88]. 
PLA2 enzymes are classified according to the homology of their nucleotide sequences 
into 14 groups designated groups I-XIV [86] or according to a historical classification 
based on functional characteristics into 4 groups: secretory PLA2 (sPLA2), cytosolic 
PLA2 (cPLA2), lipoprotein associated PLA2s platelet-activating factor acetylhydrolases, 
and Ca2+-independent PLA2 (iPLA2) [89]. 
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Calcium-independent phospholipase A2Y (iPLA2Y) is one of seven Ca2+ -independent 
PLA2 enzymes [81] (Figure 1-8). iPLA2 enzymes do not require Ca
2
+ for activity or 
translocation, range in size from 29 to 85 kDa, have an ATP-binding motif and lipase 
sites, and, with the exception of certain splice variants of iPLA2B, are membrane-
associated [90]. The first mammalian iPLA2 described was iPLA2J3 [91] (Group VIA 
PLA2) and much is now known about this enzyme including regulation of activity [92] 
and its physiological and pathological roles (see below). iPLA28 (Group VIC PLA2) is 
also called the neuropathy target esterase and is found predominately in neurons [93]. 
Three newer members, iPLA2E, sand 11 (Groups VID, VIE and VIF) possess modest 
classical PLA2 activity (sn-2 hydrolysis of phospholipids) and are efficient triglyceride 
lipases and acylglycerol transacylases [94]. Mancuso et al. and Tanaka et al. identified 
iPLA2y in non-mammalian Sf-9 (insect) and COS-7 (bacterial) cells, respectively in 2000 
[95-96]. In 2002, our laboratory reported the expression of an 85-kDa mammalian iPLA2 
selective for plasmalogen phospholipids and with an inhibitor profile not consistent with 
iPLA2B in the ER of rabbit RPTC [68]. We identified the ER iPLA2 as iPLA2y; showed 
its presence in different species including humans; confirmed its activity in various 
tissues including the brain, heart, and kidney; and excluded the presence of iPLA2B [97]. 
More recent studies identified iPLA2y in the mitochondria of rabbit renal cortex and 
RPTC [98]. 
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Calcium-Independent PLA2 Isoforms 
Historical Group PNPLA Other Names 
Classification Number Number 
iPLA2a (alpha) B.a. o.a. patatin 
iPLA2f} (beta) VIA 9 PLAlG6 
iPLAty (gamma) VIB 8 iPLA2-2 
iPLA20 (delta) VIC 6 neuropathy target esterase 
iPLA28 (epsilon) ''II) 3 adiponutrin 
iPLA2S (zeta) VIE 2 TTS-2.2 
iPLA21l (et~) VIF 4 GS2 
Figure 1-8 Different naming systems for iPLA2• Commonly used names for the 
members of the iPLA2 family. Historical classifications and group numbers have been 
reviewed [81]. Human iPLA2 genes were named patatin-like PLA2 (PNPLA) by Wilson 
et al. (2006) and each assigned a number. Other names used in the literature to identify 
each iPLA2 isoform are also listed. n.a. - not assigned. 
iPLA2p. iPLA2P is predominately expressed as a cytosolic protein and is regulated by 
several different mechanisms. The peptide sequence encodes ankyrin repeats [99] which 
participate in protein-protein oligomerization interactions of different iPLA2P splice 
variants that regulate catalytic activity [100]. The stability and activity of purified 
iPLA2P are increased in the presence of A TP [101] and activity is inhibited by 
calmodulin binding [102]. Caspase-mediated iPLA2P activation results in increased free 
fatty acid release and generates lysophosphatidylcholine, a novel chemotactic signal to 
attract phagocytes toward apoptotic cells [103]. 
iPLA2P is reported to mediate pancreatic insulin secretion [104], phospholipid 
remodeling [105], t t d Ca2+ s ore opera e entry [106], and ischemia induced 
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arrythmyogenesis [107]. Ramanadham et al. (2003) demonstrated that overexpression 
of iPLA2~ in pancreatic insulinoma cells amplifies glucose-stimulated insulin secretion 
and this effect is inhibited by the irreversible mechanism based iPLA2 inhibitor 
bromoenollactone (BEL) [104]. In a human lymphoma cell line (U937), BEL blocked 
the production of lysophospholipid acceptors for AA, and the incorporation of AA into 
membrane phospholipids [105]. In a follow-up study, overexpression of iPLA2(3 
accelerated AA incorporation into U937 cell membrane PLs, confirming the role of 
iPLA2(3 in phospholipid remodeling [108]. In summary, iPLA2(3 activity is associated 
with many physiological functions. 
Taking advantage of the fact that mice express very little iPLA2(3 activity in the heart, 
Mancuso et al. (2003) generated an iPLA2(3 transgenic mouse and utilized isolated 
perfused hearts from wild type and transgenic animals to investigate the role of iPLA2~ 
during IIR. Transgenic mice were no different than wild type mice in terms of body 
weight, heart weight or cardiac function as measured by echocardiograph, prior to 
ischemia [107]. After I1R, transgenic hearts had greatly increased amounts of FF As and 
lysophospholipids (products of PLA2 activity known to cause electrical abnormalities in 
excitable cells) and arrhythmias occurred in the transgenic hearts but not wild type [107]. 
Pretreatment with BEL completely blocked FF A and lysoPL accumulation and 
arrhythmias in the transgenic mice [107] suggesting that iPLA2(3 inhibition may lead to 
clinical benefit after myocardial infarction. In summary, iPLA2(3 has been studied 
extensively and demonstrated to play important roles in physiology and pathology. 
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iPLA2y. In 2000, two independent laboratories identified a novel iPLA2, iPLA2Y (Group 
VIB PLA2), which appeared to be constitutively membrane bound and possesses a C-
terminal SKL peroxisomal targeting sequence [95-96]. Since then, several studies have 
revealed that iPLA2y is subject to transcriptional and translational regulation, is targeted 
to various intracellular organelles and is implicated in physiology and pathophysiology of 
different organs [95, 109-110]. Importantly, rabbit iPLA2Y shares approximately 88% 
amino acid sequence homology with human iPLA2y and the sequence of its catalytic 
domain shares 100% homology, suggesting similar lipase activities [97-98]. 
Expression of iPLA2y. Based on segments of homology, between a predicted protein 
encoded on the long arm of chromosome 7 discovered during the Human Genome 
Project, and the previously identified members of the iPLA2 family, Mancuso et al. 
(2000) determined the full-length mRNA sequence of iPLA2y. In a separate laboratory, 
the C-terminal DNA sequence of iPLA2~ was compared to EST databases in an effort to 
discover a novel iPLA2 (termed iPLA2-2) [96]. Both iPLA2 enzymes had identical 782 
amino acid sequences and are homologous to iPLA2a and iPLA2~ only through the AIP 
binding and GXSTG lipase motifs. Whether expressed in insect or mammalian cells, 
iPLA2y localized to crude membrane fractions and was not detected in cytosol [95-96]. 
In COS-7 cells (kidney fibroblast cell line), transfection with full-length iPLA2y cDNA 
resulted in the expression of the expected 88 kDa protein [96]. In contrast, the full-length 
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cDNA in a rabbit reticulocyte lysate protein expression system or in Sf9 insect cells 
produced 77 and 63 kDa protein products [95]. These protein products correspond to 
translation initiation at downstream in-frame methionine residues on iPLA2Y mRNA [95, 
110]. 
Mancuso et al. (2004) performed extensive experiments designed to determine how the 
expression of different sized iPLA2Y isoforms is regulated at the transcriptional and post-
transcriptional levels. They discovered that iPLA2Y expression is repressed by 
transcriptional regulatory elements in the coding regions of iPLA2y between the 88 kDa 
and 63 kDa start sites [110]. Using electrophoretic mobility shift analyses, the binding 
of unidentified nuclear proteins to iPLA2y DNA was demonstrated which may also 
regulate transcription [110]. Initiation of translation at in-frame methionines of different 
splice variants potentially results in the expression of 92, 88, 77, 74 and 63 kDa isoforms 
and an inactive 33 kDa isoform ofiPLA2y [110]. In summary, multiple forms ofiPLA2y 
exist and the expression of iPLA2y is subj ect to rigorous control at many levels and is still 
not completely understood. 
Regulation of iPLAiY Activity. Little is known about the regulation of iPLA2y activity. 
Initial analysis of the protein revealed numerous potential phosphorylation sites including 
protein kinase A, PKC and mitogen-activated protein kinase consensus sequences [96]. 
Phosphorylation of iPLA2y at specific amino acids has not been unambiguously 
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demonstrated, but several experiments from different laboratories support the hypothesis 
that iPLA2y activity is regulated by phosphorylation. First, separation of heart proteins 
from a heart-specific iPLA2y transgenic mouse, by two dimensional gel electrophoresis, 
revealed that each molecular weight isoform of iPLA2y separated into multiple distinct 
spots with different isoelectric points (potentially representing different patterns of 
phosphorylation) [109]. Furthermore, isolated micro somes from rabbit heart and kidney 
cortex, treated with phorbol 12-myristate 13-acetate (PMA, an activator of PKC), 
demonstrated increased iPLA2 activity [111-112]. Further studies revealed renal cortex 
mitochondrial iPLA2y activity is enhanced in the presence of A TP and blocked by PKC 
inhibitor (PKCE inhibitor VI-2) [98, 113]. 
Extensive oxidative stress negatively regulates iPLA2 activity in rabbit kidney cortex 
[114] and rat myocyte micro somes [115]. tert-Butyl hydroperoxide (TBHP)-induced 
inactivation of kidney microsomal iPLA2 was reversible by adding the reducing agent 
dithiothreitol (DTT) suggesting that oxidants target protein thiols on iPLA2 [114]. 
However, non-lethal oxidant stress increased iPLA2Y expression and activity [116]. 
A calcium ionophore, A23187, was shown to activate iPLA2Y when overexpressed in 
HEK293 cells [117] suggesting that iPLA2y activity may be indirectly regulated by 
increased intracellular Ca2+ concentrations. ER-iPLA2 in rat ventricular myocytes is 
activated by the inflammatory cytokine IL-1 J3 in a BEL-sensitive manner, which may 
indicate that iPLA2y plays a role in stimulus-induced AA generation and inflammation 
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[118]. Murakami et al. (2005) also reported that AA and oleic acid release was greatly 
increased in iPLA2Y overexpressing cells when exposed to fetal calf serum and IL-
1 B. Thrombin receptor activation, by thrombin or analogs thereof, also activates 
microsomal iPLA2 in the heart leading to the production of arrhythmogenic lyso-
phosphatidylcholine and FFAs [119]. The activation of iPLA2Y by cytosolic Ca2+, 
inflammatory cytokines and thrombin demonstrate that iPLA2Y is regulated by diverse 
mechanisms and establish iPLA2y as a potential drug target for treatment of inflammatory 
diseases as well as prevention of post-ischemic arrhythmia in the heart. The regulation of 
iPLA2y in the kidney has not been elucidated. 
iPLA2¥ Pharmacological Inhibition. Predominate iPLA2 isoforms may be distinguished 
by their activity profiles in response to pharmacological inhibitors. These differential 
inhibitor profiles have been used to identify the presence of the enzymes in subcellular 
fractions and are used to investigate the roles of phospholipases in both physiological and 
pathological processes. Methyl arachidonyl fluorophosphonate (MAFP) inhibits cPLAiY 
and cytosolic iPLA2P, but not iPLA2y [68, 112]. Racemic BEL inhibits both iPLA2P and 
iPLA2Y, but the enantiomers of BEL are differentially selective for the two enzymes. 
iPLA2y is more sensitive to R-BEL than S-BEL, whereas iPLA2P is more sensitive to S-
BEL than R-BEL [68,97, 112-113]. 
iPLA2Y is sensitive to the pharmacological inhibitor racemic BEL at low micromolar 
concentrations [95], similar to iPLA2P [120]. However, other pharmacolo"gical inhibitors, 
arachidonyl trifl uoromethy lketone (AACOCF3) 
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and methylarachidonyl 
fluorophosphonate (MAFP), which inhibit iPLA2J3 at low micromolar concentrations 
[121-122] do not inhibit microsomal iPLA2 [68, 123]. Furthermore, Jenkins et al. (2002) 
demonstrated that separation of racemic BEL into the R- and S-enantiomers provides a 
mechanism to discriminate between iPLA2¥ and iPLA2J3 activity (i.e. iPLA2¥ is 10-fold 
more sensitive to R-BEL than S-BEL and iPLA2J3 is 10-fold more sensitive to S-BEL 
than R-BEL) (Figure 1-9). The use of different iPLA2 inhibitors to confirm the 
participation of iPLA2Y in various biological processes has recently been used by several 
investigators [124-125]. 
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Figure 1-9. Differential effect of Rand S enantiomers of BEL on microsomal iPLA2 
activity in RPTC, ventricular myocyte microsomes or in microsomes isolated from 
HEK293 cells. RPTC (A) were treated for 30 minutes with either (acetonitrile), R-BEL 
or S-BEL. Rabbit cardiomyocyte (B) and HEK293 (C) microsomes were isolated and 
incubated with solvent control (acetonitrile), R -BEL or S-BEL for 10 minutes prior to 
activity assays. iPLA2 activity was measured using plasmenylcholine (16:0, [3H] 18: 1) 
or substrates in the presence of 4mM EGTA. Values are means + SEM of at least 3 
separate experiments. Means with different subscripts are significantly different from 
each other, P<0.05 . Adopted from Kinsey "et. a12007. 
iPLA2¥ Substrate Specificity. The initial characterization of iPLA2¥ substrate 
specificity demonstrated that membrane fractions from Sf9 insect cells expressing iPLA2y 
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cleaved phosphatidylcholine (PC) with unsaturated fatty acids at the sn-2 position but did 
not cleave palmitic acid (16:0) from the sn-2 position [95]. Of the unsaturated fatty acids 
at the sn-2 position tested, iPLA2Y activity was highest against AA containing PC. 
iPLA2Y was also slightly more active against plasmenylcholine (PlasC) with sn-2 oleic 
acid compared to oleic acid containing PC [95]. The authors of this study cautioned that 
differences observed in the activity of a membrane bound enzyme measured using 
exogenous substrates may only reflect the rate of membrane incorporation of different 
types of PLs [95]. Several subsequent studies have further examined the activity of 
iPLA2y against different PL species using different methodologies. 
The same group later overexpressed a His-tagged iPLA2Y and was able to purify a soluble 
63 kDa isoform from Sf9 cytosol [126]. Interestingly, the soluble iPLA2y cleaved sn-2 
oleic acid more rapidly than sn-2 AA from PC with palmitic acid at the sn-l position. 
Using electro spray ionization/mass spectrometry (ESI/MS) and tandem MS it was 
determined that soluble iPLA2Y would preferentially cleave the sn-1 palmitic acid from 
PC, generating 2-arachidonyllysoPC [126]. This finding was unexpected, but potentially 
significant, since 2-arachidonyl lysoPC is a key signaling molecule with the potential to 
be metabolized to prostaglandins, leukotrienes or 2-arachidonylglycerol (an 
endocannabinoid). Soluble iPLA2Y also displayed significant lysophospholipase activity 
against I-palmitoyl lysoPC [126]. While these studies attempt to identify the activity of 
soluble iPLA2y, the substrate specificity of soluble iPLA2y may be very different than the 
isoforms of iPLA2y that are constitutively membrane bound. In intact renal cortex 
mitochondria, our laboratory showed iPLA2Y displays preferential activity against 
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plasmenylcholine with AA in the sn-2 position over oleic acid [98] and further studies 
revealed a preference for AA in both stressed and basal conditions in renal cortical 
mitochondria [127]. 
The activity of microsomal iPLA2 in the heart using different radiolabeled PL substrates 
and reverse-phase HPLC quantitation of PL abundances has also been studied. Rabbit 
ventricular myocyte iPLA2 preferred PlasC 16:0;18:1 over PC 16:0;18:1 and liberated 
significantly more sn-2 AA than oleic acid from synthetic PC, PlasC and 
plasmanylcholine PLs [123]. Furthermore, thrombin stimulation of rabbit ventricular 
myocytes caused a BEL-sensitive decrease in abundance of sn-2 AA containing PlasC 
and PlasE and no change in PC or PE containing sn-2 AA [128]. In the kidney, 
microsomal iPLA2 also prefers PlasC over PC PLs with oleic acid at the sn-2 position, 
but the AA and polar head group selectivity has not been determined [68]. 
In summary, different substrate specificities of iPLA2Y have been reported which may 
reflect differences in techniques used for measurement (e.g. radiolabeled synthetic 
substrates vs. ESIIMS of changes in cellular phospholipid abundances), differences in the 
isoform responsible for activity (e.g. cytosolic His-tagged vs. overexpressed membrane-
bound vs. native microsomal iPLA2Y) or differences in the regulatory mechanisms in 
place in the different cellular extracts used for measurement (e.g. phosphorylation state of 
iPLA2y, presence of Ca
2
+ or ROS). Overall, when acting as a classical PLA2, iPLA2Y 
preferentially cleaves AA from the sn-2 position of vinyl ether containing PLs 
(plasmalogens ). 
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Intracellular Localization of iPLA2y. The localization of iPLA2y to crude membrane 
fractions when overexpressed in Sf9 and COS-7 cells and the presence of a C-terminal 
SKL peptide sequence led to speculation that this enzyme was targeted to peroxisomes 
[95]. In fact, the first demonstration of native iPLA2¥ expression was the 63 kDa isoform 
in purified rat liver peroxisomes [129]. Subsequently, Mancuso et al. (2004) reported 
that higher molecular weight isoforms were found in rat heart mitochondria and nuclear 
...... 
fractions. The mechanism for mitochondrial targeting was determined to be an N-
terminal amino acid sequence present in the 88, 77 and 74 kDa isoforms but absent in the 
63 kDa iPLA2¥ [110]. Additionally, cytosolic iPLA2¥ was observed following 
overexpression in a transgenic mouse [109] Our laboratory demonstrated the expression 
of an iPLA2 activity in the microsomal (ER) fraction of rabbit RPTC that is sensitive to 
BEL [68] and Beckett et al. (2006) reported that the majority of human platelet iPLA2 
activity is cytosolic and is inhibited by R-BEL, an iPLA2¥ selective pharmacological 
inhibitor. A strongly immunoreactive protein of approximately 50 kDa in platelet cytosol 
was detected with an anti-iPLA2y antibody [130]. Later, we demonstrated the presence of 
iPLA2¥ in renal mitochondria and excluded the presence of iPLA2P activity [68, 97-98]. 
In summary, iPLA2¥ protein and/or activity has been identified in peroxisomes, 
mitochondria, nuclei, microsomes and cytosol and its presence in other subcellular 
compartments has not been ruled out. 
Mitochondrial iPLA2• Ca
2
+ -independent PLA2 activity has been demonstrated in rat 
liver mitochondria [131] and in rabbit ventricular myocyte mitochondria [132]. The 
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isoform identity of each iPLA2 was hypothesized to be iPLA2P, based on positive 
immunoblot analyses with a commercially available iPLA2P antibody and sensitivity of 
the activity to racemic BEL [131-132]. In rat liver mitochondria the iPLA2 is supposedly 
activated by dissipation of the mitochondrial membrane potential and is hypothesized to 
facilitate removal of poorly functioning mitochQndria by destruction of mitochondrial 
phospholipids [131]. Prevention ofIlR-induced cardiac infarct in isolated perfused hearts 
by BEL was attributed solely to mitochondrial iPLA2 inhibition and the contribution of 
the well-described microsomal iPLA2 in rabbit ventricular myocytes was not taken into 
account [132]. Both mitochondrial iPLA2 are localized to membrane fraction of 
mitochondria and the rabbit heart iPLA2 was specifically localized to the inner 
mitochondrial membrane [132]. Gross and colleagues have demonstrated the presence 
of iPLA2y protein in mitochondria from rat heart with an iPLA2Y antibody, but 
mitochondrial iPLA2Y activity was not measured [110]. It is possible that both iPLA2 
activities described previously in rabbit heart and rat liver are the result of iPLA2y and not 
iPLA2P, based on the inhibition profile of these mitochondrial enzymes. These studies 
report that AACOCF3 either does not inhibit mitochondrial iPLA2 activity [131] or has no 
effect on ischemia-induced infarct size [132], while racemic BEL potently inhibits both 
endpoints in these studies. The inhibitor sensitivity profile (BEL-sensitive and 
AACOCF3-insensitive) matches iPLA2Y and not iPLA2P. In 2007, Kinsey et. al. 
identified iPLA2y in rabbit renal proximal tubules by immunoblot analysis and activity 
studies and excluded the presence of iPLA2(3 [98]. Interestingly, pharmacological 
inhibition of iPLA2y with BEL potentiated oxidant-induced mitochondrial lipid 
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peroxidation and swelling, but prevented Ca2+ -induced mitochondrial permeability 
transition (MPT) by preventing arachidonic acid release in isolated mitochondria [98, 
113]. 
Endoplasmic Reticulum iPLA2y Prior to the identification of mitochondrial iPLA2y 
most studies did not take into account differential subcellular localization of iPLA2y and 
activity was considered either microsomal (ER) or peroxisomal. Additionally, lack of 
organelle specific inhibitors of iPLA2Y has made identification of differential function of 
iPLA2y within organelle difficult. Therefore studies are limited to isolated organelle to 
determine organelle specific activity. Interestingly, pharmacological inhibition of iPLA2y 
with the selective inhibitor bromoenollactone (BEL) reduced cisplatin-induced apoptotic 
renal proximal tubule cell (RPTC) death and in contrast, iPLA2y inhibition potentiated 
oxidant-induced lipid peroxidation and necrotic RPTC death [68, 98]. These data provide 
further evidence that iPLA2y may have divergent roles in cell injury and death, which 
may be explained by unique roles and functions within subcellular compartments [81]. 
These data implicate" iPLA2y as a mediator of apoptotic cell death and as a protectant in 
oxidant-induced necrotic cell death. Recent studies in our laboratory used iPLA2y-
specific shRNA to decrease iPLA2y activity and expression in RPTC [116]. While the 
loss of mitochondrial iPLA2Y was correlated with decreased mitochondrial uncoupled 
respiration, these studies pointed to ER- iPLA2y in the lipid peroxidation 
repair/prevention pathway because knockdown of ER- iPLA2Y was correlated with 
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increased lipid peroxidation [116]. These studies underscore the need of further studies to 
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Figure 1-10. Small hairpin ribonucleic acid (shRNA)-mediated decreases in 
mitochondrial and ER- iPLA2y in RPTC. Confluent RPTCs were exposed to either 
adenoviral iPLA2y or scramble shRNA and cultured normally for 4 days. 
iPLA2y expression was measured by immunoblot analysis (A, B) and iPLA2 activity was 
measured (C, D) in mitochondrial (A, C) and ER (B, D) fractions at 24, 48, 72, and 96 h 
after exposure. The amount of iPLA2y expression and activity in cells exposed to 
iPLA2y shRNA is expressed as means +SEM, percentage of iPLA2y expression and 
activity in cells exposed to scramble shRNA for the same amount of time. Insets show 
representative immunoblots. Means with different superscripts are significantly different 
from each other (P< 0.05, n = 4-5). Note: ER- iPLA2y expression and activity decreases 
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Figure 1-11. Effects of decreased iPLA2¥ expression on RPTC lipid peroxidation. 
The thiobarbituric acid-reactive substances (TBARS) assay was performed in noninfected 
(control), scramble shRNA, and iPLA2¥ shRNA adenovirus-treated RPTCs at 24, 48, and 
72 h after virus exposure as a measure of cellular lipid peroxidation. Data are presented 
as means + SEM, percentage of control TBARS formation. Means with different 
superscripts are significantly different from each other (P < 0.05, n=4). Note: lipid 
peroxidation occurred at 24 h and correlated with decreases in ER - iPLA2¥ and prior to 
decreases in mitochondrial- iPLA2¥ activity and expression. From Kinsey et. al [116]. 
iPLA2¥ in the Brain. iPLA2¥ has been suggested to play a protective role in the brain 
during oxidant stress. Inhibition of iPLA2¥ prior to oxidant treatment in astrocytes 
potentiated oxidant induced cell death[133]. Mice genetically ablated of iPLA2¥ 
exhibited cognitive dysfunction and cortical tissues exhibited multiple inclusion bodies 
following immunohistochemical staining [134-136]. These consequences of genetic 
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the heart [138-139]. The toxicity of doxorubicin in the heart is related to increased ROS 
production, causing lipid peroxidation in cardiac membranes, and anthracyclines also 
prevent the repair of lipid peroxidation by inhibiting microsomal iPLA2 [137]. Similar to 
the effects of iPLA2 inhibition on oxidant-induced necrosis in the kidney, BEL 
pretreatment significantly potentiated lactate dehydrogenase release from cardiac 
myocytes exposed to doxorubicin [139]. Most recently, Mancuso et. al. reported that 
mice genetically ablated of iPLA2Y were more vulnerable to cardiac stress (transverse 
aortic constriction) [136]. 
iPLA2¥ in the Kidney. Inhibition of microsomal iPLA2 in RPTC with racemic BEL, 
potentiates lipid peroxidation and necrotic cell death induced by diverse oxidants but has 
no effect on non-oxidant induced necrosis [68] (Figure 1-10). Effects of BEL on 
glutathione, ATP, GTP and mitochondrial function were ruled out, and BEL-induced 
potentiation of oxidant-induced lipid peroxidation was observed well before cell death 
was detectable [68] (Figure 1-11). In a subsequent study, treatment ofRPTC with TBHP 
resulted in the significant loss (presumably by oxidative damage) of 4 individual PL 
species (of 28 total measured), but pretreatment with BEL caused a TBHP-induced loss 
of 15 out of28 PLs [114]. 
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Figure 1-12. Effect of iPLA2 inhibition on necrotic cell death in RPTC. RPTC were 
treated with diluent or racemic BEL (5 f.lM) 30 minutes prior to exposure to the oxidants: 
TBHP (200 f.lM) for 24 hr; cumene H20 2 (200 f.lM) for 24 hr; menadione (10 f.lM) for 12 
hr; duraquinone (400 f.lM) for 24 hr and cisplatin (400 f.lM) for 24 hr, or the non-oxidant, 
antimycin A (0.3 f.lM) for 4 hr, and necrotic cell death measured by flow cytometry as the 
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Figure 1-13. Effect of iPLA2 inhibition on lipid peroxidation in RPTC. RPTC were 
treated with diluent or racemic BEL (5 ~M) 30 minutes prior to exposure to TBHP (200 
~M), cumene H20 2 (200 ~M), menadione (10 ~M), duraquinone (400 ~M), cisplatin 
(400 ~M) and antimycin A (0.3 ~M) each for 2 hr, and prior to any increase in cell death, 
lipid peroxidation (malondialdehyde (MDA) formation) estimated using the 
thiobarbituric acid reactive substances assay. From Cummings et. al [68]. 
In the same RPTC model, inhibition of microsomal iPLA2 blocks non-oxidant mediated 
cisplatin (50 ~M)-induced apoptosis (PS extemalization, chromatin condensation and 
caspase 3 activity) but not p53 nuclear translocation [112]. In addition, activation of 
microsomal iPLA2 with PMA increased cisplatin-induced annexin-V staining and cell 
shrinkage [112]. These results suggest that, during cisplatin-induced RPTC apoptosis, 
iPLA2 activity regulates caspase activation presumably by an AA-mediated mechanism 
[140]. Cisplatin is a widely used chemotherapeutic drug with a major dose-limiting side 
effect of renal toxicity. Similarly, Kinsey et. al showed that mitochondrial 
iPLA2y mediates Ca
2+-induced mitochondrial swelling through a AA-dependent 
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mechanism [98]. Overall, the role of iPLA2 in RPTC necrosis and apoptosis suggest that 
manipulation of this enzyme in the setting of ARF may provide novel therapeutic 
possibilities. 
iPLA2¥ in Skeletal Muscle. Mancuso et al reported skeletal muscle lacking the 
bioenergetic capacity of Interestingly, Y oda et al. also generated mice null of iPLA2Y and 
reported in skeletal muscle, increased lipid peroxidation, the induction of oxidative stress 
related proteins, and, similarly to the work of Mancuso et aI., alterations in cardiolipin 
content and mitochondrial dysfunction[141]. Skeletal muscle ablated of iPLA2y 
displayed atrophy of myofilaments, reduced fiber diameter, and alterations in prostanoid 
and phospholipids content. Mancuso et al. reported similarly mitochondrial dysfunction 
in iPLA2y -/ - mice. Skeletal muscle mitochondria exhibited reduced state 3 respiration 
and altered cardiolipin composition. Together, these changes seemingly resulted in mice 
insensitive to high fat diet induced weight gain and reduced their exercise endurance 
[134, 136, 141]. 
iPLA2¥ in Other Tissues. In the first demonstration of native iPLA2y expression, Yang 
et ai. (2003) showed that hepatic peroxisomes possess a 63 kDa protein immunoreactive 
to an anti-iPLA2y antibody. Based on the phospholipid content of peroxisomes from rat 
liver (exhibiting a relatively high content of sn-2 AA), it was hypothesized that iPLA2¥ 
may playa role in cellular signaling [129]. 
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Both iPLA2¥ and iPLA2P were demonstrated to participate in hormone-induced 
differentiation of preadipocytes using RNA interference and R- and S-BEL [142]. 
Temporal patterns of iPLA2 expression during differentiation were described and use of 
the siRNA and pharmacological inhibitors for both isoforms prevented differentiation 
[142]. In addition, increased expression of the 63 kDa isoform of iPLA2¥ was 
demonstrated by immunoblot analysis in obese vs. lean rats [142]. These results suggest 
that iPLA2 enzymes (including iPLA2¥) may be involved in the progression of obesity. 
Most recently, Mancuso et al. showed that mice genetically ablated of iPLA2¥ were 
resistant to high fat diet-induced weight gain and insulin resistance[134]. 
Human platelets possess a cytosolic isoform of iPLA2¥ of approximately 50 kDa [130]. 
Similar to ventricular myocytes and aortic. endothelial cells, platelet iPLA2y is activated 
by thrombin and the activation is completely blocked by BEL [130]. Thrombin 
stimulation caused the BEL-sensitive production of AA, lysoPlasC, and thromboxane A2 
over the course of several minutes [130]. iPLA2Y mediated platelet activation may 
represent another potentially inhibitable function of iPLA2Y in multiple settings where 
clotting is unwanted. 
Conclusions and Rationale. In conclusion, acute kidney injury (AKI) and chronic 
kidney disease (CKD) are becoming more prevalent and have high morbidity and 
mortality that have been unchanged for many years. Current therapeutics targeted 
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towards preventing or treating kidney injury and disease have been unsuccessful. 
Calcium-independent phospholipase A2Y (iPLA2y) is one of seven Ca
2
+ -independent 
PLA2 enzymes and represents a potential thearapeutic target in kidney disease [81]. Our 
studies in renal cells showed that iPLA2Y has a unique subcellular localization in that its 
expression and activity were found in both the endoplasmic reticulum (ER) and the 
mitochondria, while iPLA2P activity was not present [68, 97-98]. We also determined 
that iPLA2Y has divergent roles in cell injury and death, which may be explained by 
unique roles and functions within subcellular compartments [81]. Recent studies in our 
laboratory using iPLA2y-specific shRNA to decrease iPLA2y activity and expression in 
RPTC confirmed its role in preventing lipid peroxidation and preserving mitochondrial 
function and viability under basal conditions [116]. While the loss of mitochondrial 
iPLA2y was correlated with decreased mitochondrial uncoupled respiration, these studies 
pointed to ER- iPLA2y in the lipid peroxidation repair/prevention pathway because 
knockdown of ER- iPLA2y was correlated with increased lipid peroxidation. However, 
no studies have elucidated the role of iPLA2Y in the ER nor has the mechanism by which 
iPLA2¥ preserves phospholipid homeostasis been determined. The goals of these studies 
are to elucidate the role of ER- iPLA2¥ in oxidant-induced ER lipid peroxidation, loss of 
lipid homeostasis, Ca2+ release and renal cell death. 
Recently, Mancuso et al. generated mice null of iPLA2¥ by genetically ablating the 
enzyme's active site [136]. These mice were more vulnerable to cardiac stress 
(transverse aortic constriction), resistant to high fat diet-induced weight gain, and 
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exhibited cognitive dysfunction and multiple bioenergetic dysfunctional phenotypes, such 
as cold intolerance and reduced exercise endurance[134-136]. These consequences of 
genetic ablation of iPLAl'Y were attributed to loss of cardiolipin (a lipid found primarily 
in mitochondria) homeostasis, resulting in mitochondrial dysfunction. Interestingly, 
y oda et al. also generated mice null of iPLA2y and reported in skeletal muscle, increased 
lipid peroxidation, the induction of oxidative stress related proteins, and, similarly to the 
work of Mancuso et aI., alterations in cardiolipin content and mitochondrial 
dysfunction[141]. Additionally, these findings provide evidence that loss of iPLA2y-
induced oxidative stress and mitochondrial dysfunction leads to organ dysfunction in 
brain, heart, and skeletal muscle. However, the role of ER- iPLA2y in oxidant- or genetic 
ablation- induced lipid peroxidation has not been investigated nor has its role in organ 
dysfunction been elucidated. 
Based on the current knowledge of the pathophysiology of AKI and CKD and the biology 
of PLA2 enzymes, especially iPLA2 in the kidney, the current project was developed. 
The specific aims were as follows: 1) to determine the role of ER- iPLA2y in oxidant-
induced lipid peroxidation, Ca2+ release, and renal cell death, 2) to elucidate the 
mechanism by which ER-iPLA2Y maintains phospholipid homeostasis following oxidant 
injury and 3) determine the consequences of iPLA2y ablation in vivo on kidney function 
and oxidant injury. 
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Chapter 2 
Visualization and quantification of endoplasmic reticulum Ca2+ in renal cells using 
confocal microscopy and Fluo5F 
ABSTRACT 
Sarcoplasmic/endoplasmic reticulum (ER) Ca2+ is the most abundant store of intracellular 
Ca2+, and its release is an important trigger of physiological and cell death pathways. 
Previous work in our laboratory revealed the importance of ER Ca2+ in toxicant-induced 
renal proximal tubular cell (RPTC) death. The purpose of this study was to evaluate the 
use of confocal microscopy and Flu05F, a low affinity Ca2+ indicator, to directly monitor 
changes in RPTC ER Ca2+. Fluo5F staining reflected ER Ca2+, resolved ER structure, and 
showed no colocalization with tetramethyl rhodamine methyl ester (TMRM), a marker of 
mitochondrial membrane potential. Thapsigargin, an ER Ca2+ pump inhibitor, decreased 
ER fluorescence by 30% and 55% at 5 and 15 min, respectively, whereas A23187, a Ca2+ 
ionophore caused more rapid ER Ca2+ release (55% and 75% decrease in fluorescence at 
5 and 15 min). 
Carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP), a mitochondrial 
uncoupler, added at the end of the experiment, further decreased ER fluorescence after 
thapsigargin treatment, revealing that thapsigargin did not release all ER Ca2+. In 
contrast, FCCP did not decrease ER fluorescence after A23187 treatment, suggesting 
complete ER Ca2+ release. ER Ca2+ release in response to A23187 or thapsigargin 
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resulted in a modest but significant decrease in mitochondrial membrane potential. These 
data provide evidence that confocal microscopy and Flu05F are useful and effective tools 
for directly monitoring ER Ca2+ in intact cells. 
Introduction 
Ca2+ acts as a universal second messenger and regulates numerous cellular functions 
including metabolism, motility, and transport [ 44]. Loss of Ca2+ homeostasis is critical to 
many disease processes and is a major component of cell death pathways including 
necrosis, apoptosis, and autophagy [45-51]. Sarcoplasmic/endoplasmic reticulum (ER) 
Ca2+ is the most abundant store of intracellular Ca2+ and its disruption often initiates the 
deleterious cascade of events leading to cell death and dysfunction [48-54]. 
Traditional methods of measuring of ER Ca2+ are indirect or require difficult probe 
loading techniques (i.e. membrane permeabilization, microinjection, or fused cell 
hybrids). For example, human embryonic kidney cells require 1 h of dye loading (2 flM 
Fluo-3 at room temperature) and extracellular Ca2+ chelation using BAPTA or EGTA, 
just to monitor increases in cytosolic Ca2+ as an indirect measure ofER Ca2+ stores [143]. 
To monitor ER Ca2+ directly, Montero and Robert et al. engineered an ER-targeted 
aequorin chimera, a Ca2+-sensitive photoprotein with a lower affinity for Ca2+. However, 
in HeLa and skeletal muscle cells, the aequorin chimera was rapidly saturated by the high 
Ca2+ concentrations within the ER and required a non-physiological reduction of ER Ca2+ 
to detect changes in Ca2+ stores [144-145]. 
Primary cultures of renal proximal tubular cells (RPTC) are highly aerobic, 
gluconeogenic, and exhibit robust transport capacity, making them ideal for the study of 
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kidney tubular function and injury [146-147]. Previous work in our laboratory revealed 
the importance of ER Ca2+ in toxicant-induced kidney injury; although, the mechanism 
by which Ca2+ plays such a pivotal role is not completely understood [48, 50, 52-53, 68, 
112]. 
Confocal mIcroscopy is a useful method for the visualization and quantification of 
fluorophores at the subcellular level in living cells, and is compatible with most Ca2+ 
indicators. Chemical fluorescent (UV and visible-wavelength excitation fluorescent 
indicators) and bioluminescent calcium indicators (Ca2+ binding photoproteins and GFP-
based Ca2+ indicators) differ in their characteristics (loading requirements, 
excitation/emission spectrum, permeability, compartmentalization, relative brightness, 
and Ca2+ affinity) and have inherent drawbacks (i.e., dye leakage, cytotoxicity, bleaching, 
autofluorescence, intracellular buffering, and lack of ion specificity)[148]. FluoSF is a 
chemical fluorescent Ca2+ indicator with a lower affinity for Ca2+ (Kd ---2.3 ~M), limited 
cytoxicity and bleaching, and high Ca2+ specificity, making it ideal for studying ER Ca2+. 
The purpose of this study was to evaluate the use of confocal microscopy and Fluo5F for 
directly monitoring changes in ER Ca2+ in RPTC. 
MATERIALS AND METHODS 
Materials 
Female New Zealand White rabbits (1.5-2.0 kg) were purchased from Myrtle's Rabbitry 
(Thompson Station, TN). Tetramethyl rhodamine methyl ester (TMRM) and Fluo-SF-
AM were purchased from Molecular Probes, Invitrogen (Carlsbad, CA). All other 
chemical and materials were obtained from Sigma Chemical (St. Louis, MO). 
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Isolation of Rabbit RPTC and Culture Conditions 
Rabbit RPTC were isolated using the iron oxide perfusion method and grown to 
confluence in 3S-mm tissue culture dishes under improved conditions as previously 
described [146-147]. The culture medium was a 1:1 mixture of Dulbecco's modified 
Eagle's mediumIHam's F-12 medium (without glucose, phenol red, or sodium pyruvate) 
supplemented with 15 mM HEPES buffer, 2.5 mM L-glutamine, 1 JlM pyridoxine HCI, 15 
mM sodium bicarbonate, and 6 mM lactate. Hydrocortisone (50 nM), selenium (5 ng/ml), 
human transferrin (5 Jlg/ml), bovine insulin (10 nM), and L-ascorbic acid-2-phosphate (SO 
JlM) were added daily to fresh culture medium. 
RPTC Loading 
RPTC were loaded with 2 JlM Fluo-SF-AM (FluoSF) and 100 nM TMRM for 20 min at 
37° C, washed twice with 37° C phosphate buffered saline, and media was replaced. 
Then, 1 flM FluoSF and 40 nM TMRM were added to the media to maintain dye 
equilibrium and incubated for 30 min at 37° C prior to imaging. The TMRM loading 
protocol was modified from Lemasters and Ramshesh [149]. 
Microscopic Imaging and Analysis 
RPTC were imaged on a Leica Microsystems, TCS SP2 AOBS laser scanning confocal 
microscope (LSCM) using standardized pinhole, gain, and black level settings. A 63XO.9 
NA water-immersion objective was used in an upright microscope configuration. All 
images were acquired at 8-bit resolution and at 1024XI024 with a line averaging of two. 
RPTC were monitored for 10 min prior to treatment to establish baseline. Then, RPTC 
were treated and monitored an additional 15 min prior to Carbonylcyanide-p-
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trifluoromethoxyphenylhydrazone (FCCP, 1 J.!M) addition to depolarize mitochondria. 
Images were acquired in I-min intervals during the course of experiments. To quantify 
data, images were analyzed using Adobe Photoshop. Mean intensities of images in the 
green and red channel after background subtraction were interpreted as a quantitative 
measure of ER Ca2+ and mitochondrial membrane potential, respectively. Values are 
graphed as the percent mean intensity of each subsequent image vs. mean intensity of the 
image taken at time zero. Images comprise of7-10 cells. 
Statistical Analysis 
RPTC isolated from one animal represents one experiment (N==I). Data are presented as 
means ± SE, and multiple means were compared using Student-Newman-Keuls test at 
each time point. Means with values p<0.05 were considered statistically significant. 
RESULTS AND DISCUSSION 
To investigate the use of confocal microscopy to monitor ER Ca2+ dynamics in RPTC, 
Flu05F fluorescence was monitored as described above (Fig. 2-1a). Flu05F fluorescence 
revealed a reticular pattern around nuclei void of staining. The peripheral granularity of 
staining and scarcity of staining at the cell margins provided evidence that the probe is 
not fluorescing in the cytosol. To confirm that Flu05F was not in the mitochondria, RPTC 
were loaded with tetramethyl rhodamine methyl ester (TMRM) , a marker of polarized 
mitochondria. TMRM staining (Fig. 2-1 b) had a punctuate/tubular pattern unlike Flu05F 
staining with no co-localization (Fig. 2-1 c), confirming that Flu05F does not reflect 
mitochondrial Ca2+, the second most significant storage/buffering compartment for 
intracellular Ca2+ [ 47] . 
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Figure 2-1. Morphology of Renal Proximal Tubule Cells (RPTC) co-loaded with 
Fluo5F and TMRM using confocal microscopy. RPTC were co-loaded with Flu05F (2 
JlM) and TMRM (100 nM) as described in the materials and methods. Green 
fluorescence of Flu05F and red fluorescence of TMRM were imaged by laser scanning 
confocal microscopy. The white bar represents 10 Jlm. Flu05F fluorescence (A) 
represents endoplasmic reticulum (ER) Ca2+, TMRM fluorescence (B) represents 
polarized mitochondria, and there was no co-localization (C). 
We investigated the use of Flu05F to monitor real-time changes in RPTC ER Ca2+. 
TMRM was used to measure mitochondrial membrane potential. In control cells, both 
Fluo5F and TMRM fluorescence intensity, morphology, and resolution were maintained 
over time (Fig. 2-2). Carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP), a 
mitochondrial uncoupler, was added at the end of each experiment to cause mitochondrial 
depolarization and indirectly ER Ca2+ release, due to A TP depletion and cessation of 
















Figure 2-2. ER Ca2+ release RPTC exposed to A23187 and thapsigargin. RPTC were 
loaded with Fluo5F and TMRM (see in Fig. 1-1), monitored for 10 min to establish 
baseline, exposed to diluent (DMSO, Control), A23187 (10 J..lM), or thapsigargin (10 J..lM) 
for 15 min, and then exposed to FCCP (1 J.!M), a mitochondrial uncoupler. Open arrows 
represent time of A23187 or thapsigargin treatment and closed arrows represent the 
addition of FCCP. Green fluorescence (A) and red fluorescence (B) represents ER Ca2+ 
and mitochondrial polarization, respectively. Note the more rapid ER Ca2+ release (A) in 
response to A23187 exposure compared to thapsigargin and the rapid loss of 
mitochondrial polarization (B) in response to FCCP. 
We then explored the effects of two pharmacological agents known to alter ER Ca2+. 
RPTC were treated with the SERCA inhibitor, thapsigargin, and the Ca2+ ionophore, 
A23187. Thapsigargin decreased ER Ca2+ over several min (Fig. 2-2A), which was more 
indicative of ER Ca2+ leakage than receptor-dependent ER Ca2+ release that is 
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characterized by DAG, ryanodine, and IP3 receptor sensitive stores [44, 150-151]. In 
contrast, A23187 caused a more rapid release of ER Ca2+, an anticipated finding due to 
its ionophore activity. 
Temporal and incremental changes in ER Ca2+ release and mitochondrial membrane 
potential were quantified (Fig. 2-3). A23187 decreased fluorescence by 50% and 70% at 
5 and 15 min after treatment, respectively, and FCCP addition did not decrease 
fluorescence further. Thapsigargin decreased fluorescence by 25% and 55% at 5 and 15 
min after treatment, respectively. In contrast to A23187, FCCP addition further decreased 
fluorescence after thapsigargin, providing evidence that thapsigargin did not completely 
release all ER Ca2+ stores under these conditions. 
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Figure 2-3. Quantification of A23187- and thapsigargin- induced ER Ca2+ release in 
RPTC. RPTC were co-loaded with Flu05F and TMRM, treated as described in fig. 2, and 
images acquired as described in Materials and Methods. Values are mean intensities of 
images in the green channel ± SE and loss of intensity represents ER Ca2+ release. The 
open arrow represents exposure to A23187, thapsigargin, or diluent control and the 
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closed arrow represents the addition of FCCP. Note the more rapid ER Ca2+ release after 
A23187 exposure compared to thapsigargin and an additional loss of fluorescence with 
FCCP following thapsigargin exposure. 
The advantage of this approach is that ER Ca2+ stores are measured directly, allowing 
observation of spatiotemporal differences between A23187- and thapsigargin-induced ER 
Ca2+ release that would otherwise be masked by measuring cytosolic free Ca2+. 
Interestingly, Jiang et ale reported a higher rate and magnitude of cytosolic Ca2+ increase 
in response to A23187 over thasigargin using Fluo-3, but this approach required chelation 
of extracellular Ca2+ prior to treatment [143]. 
The effect of ER Ca2+ release on mitochondrial polarization was monitored using TMRM 
(Fig. 2-4). A23187- and thapsigargin-induced ER Ca2+ release decreased TMRM 
fluorescence by approximately 10%. In contrast, FCCP, the mitochondrial uncoupler 
added at the end of each experiment, decreased TMRM fluorescence by 60%, reflecting 
complete mitochondrial depolarization. Together, these data reveal that ER Ca2+ release 
produced by A23187 or thapsigargin partially decreases mitochondrial polarization and is 
consistent with previous reports [152]. 
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Figure 2-4. Quantification of A23187- and thapsigargin-induced mitochondrial 
depolarization in RPTC. See above for experimental details. Values are mean 
intensities of images in the red channel ± SE and loss of intensity represents 
mitochondrial depolarization. The open arrow represents exposure to A23187, 
thapsigargin, or diluent control and the closed arrow represents the addition of FCep. 
Note the decrease in mitochondrial polarization following A23187 or thapsigargin 
exposure compared with control and the rapid loss of mitochondrial polarization 
following Feep exposure in all groups. 
In conclusion, confocal microscopy and Flu05F are valuable tools for visualization of 
spatiotemporal dynamics of ER Ca2+ release in complex cellular systems in real time and 
will aid in our understanding of cellular dynamics and death. 
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Chapter 3 
The Role of Endoplasmic ReticulumCa2+ -Independent Phospholipase A2y in 
Oxidant-induced Lipid Peroxidation, Ca2+ Release, and Renal Cell Death 
Abstract 
Oxidant-induced lipid peroxidation and cell death are major components of ischemia-
reperfusion and toxicant injury. Our previous studies showed that renal proximal tubular 
cells (RPTC) express Caz+ -independent phospholipase Azy (iPLAzY) in endoplasmic 
reticulum (ER) and mitochondria and that iPLA2y is cytoprotective. Our present studies 
reveal the role ofER- iPLA2y in oxidant-induced ER lipid peroxidation, Ca
2
+ release, and 
cell death. Oxidant tert-butyl hydroperoxide (TBHP) caused ER lipid peroxidation and 
Ca2+ release in isolated rabbit kidney cortex microsomes. ER- iPLA2y inhibition, using 
bromoenol lactone (BEL), potentiated both oxidant-induced ER lipid peroxidation and 
Ca2+ release. Assessment of fatty acids using electrospray ionization-mass spectrometry 
revealed that ER- iPLA2y mediates the TBHP-induced release of arachidonic acid (20:4), 
linoleic acid (18:2), and their oxidized forms (18:2-0H, 18:2-00H, 20:4-0H, 20:4-00H, 
20:4-(OH)3). iPLA2Y inhibition also accelerated oxidant-induced ER Ca2+ release in 
RPTC. Depletion of RPTC ER Ca2+ stores with thapsigargin, an ER Caz+ pump inhibitor, 
prior to TBHP exposure reduced necrotic cell death and blocked the potentiation of 
TBHP-induced necrotic cell death by BEL. Together, these data provide strong evidence 
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that ER- iPLA2y protects renal cells from oxidant-induced necrotic cell death by releasing 
unsaturated and/or oxidized fatty acids from ER membranes, thereby preserving ER 
membrane integrity and preventing ER Ca2+ release. 
Introduction 
Phospholipase A2 (PLA2) enzymes catalyze the hydrolysis of fatty acids at the sn-2 
position of glycerophospholipids resulting in the production of a free fatty acid and a 
lysophospholipid [86]. Free fatty acids and their metabolites are biologically active in 
such processes as inflammation, cell signaling, and cell death. Arachidonic acid, for 
example, is metabolized to prostaglandins, prostacyclins, thromboxanes and leukotrienes, 
all of which playa role in inflammatory responses and cell signaling [87]. The resulting 
lysophospholipids serve as substrates for the re-esterification of free fatty acids by CoA-
dependent acyltransferases and are also cell signaling molecules [82]. The deacylation 
and reacylation of phospholipids is termed "The Lands Cycle" and may be involved in 
membrane remodeling and the maintenance of membrane homeostasis under 
physiological and pathological conditions. However, there are limited studies 
investigating this phenomenon in cellular systems [88]. 
Calcium-independent phospholipase A2Y (iPLA2Y is one of seven Ca2+ -independent PLA2 
enzymes [81]. Our studies in renal cells showed that iPLA2y has a unique subcellular 
localization in that its expression and activity were found in both the endoplasmic 
reticulum (ER) and the mitochondria, while iPLA2Y activity was not present [68, 97-98]. 
We also determined that iPLA2y has divergent roles in cell injury and death, which may 
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be explained by unIque roles and functions within subcellular compartments [81]. 
Pharmacological inhibition of iPLA2'Y with the selective inhibitor bromoenol lactone 
(BEL) reduced cisplatin-induced apoptotic renal proximal tubule cell (RPTC) death and 
prevented Ca2+ - induced mitochondrial permeability transition by preventing arachidonic 
acid release in isolated mitochondria [112-113]. In contrast, iPLA2y inhibition 
potentiated oxidant-induced lipid peroxidation and necrotic RPTC death [68, 98]. These 
data implicate iPLA2Y as a mediator of apoptotic cell death and as a protectant in oxidant-
induced necrotic cell death. 
Recent studies in our laboratory using iPLA2y -specific shRNA to decrease iPLA2y 
activity and expression in RPTC confirmed its role in preventing lipid peroxidation, 
maintaining phospholipid homeostasis, and preserving mitochondrial function and 
viability under basal conditions [116]. While the loss of mitochondrial iPLA2y was 
correlated with decreased mitochondrial uncoupled respiration, these studies pointed to 
ER- iPLA2Y in the lipid peroxidation repair/prevention pathway because knockdown of 
ER- iPLA2Y was correlated with increased lipid peroxidation. However, no studies have 
elucidated the role of iPLA2Y in the ER nor has the mechanism by which iPLA2y 
preserves phospholipid homeostasis been determined. The goals of the present study 
were to understand the role of ER-iPLA2Y in oxidant-induced ER lipid peroxidation, fatty 
acid release, Ca2+ release and necrotic cell death. 
Materials and Methods 
Female New Zealand White rabbits (1.5-2.0 kg) were purchased from Myrtle's Rabbitry 
(Thompson Station, TN). FIuo-4 pentapotassium salt and FIuo-SF-AM (Fluo5F) were 
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purchased from Molecular Probes Invitrogen (Eugene, OR). All other chemicals and 
materials were obtained from Sigma Chemical (St. Louis, MO) or reported previously 
[68,97-98,112,116,153]. 
Isolation of Microsomes. Microsomes were isolated by differential centrifugation from 
homogenized rabbit kidney cortex in ice-cold isolation buffer 1 (270 mM sucrose, 5 mM 
Tris-HCL, 1 mM EGTA, pH 7.4) for lipid peroxidation studies as described by Kinsey et 
al. or isolation buffer 2 (210 mM mannitol, 70 mM sucrose, 2 mM HEPES, pH 7.4) for 
Ca2+ uptake studies as described by Schieppati et al. [98, 154]. Microsomes were 
resuspended for immediate use in lipid peroxidation buffer (150 mM KCL, 30 mM Tris-
HCL, pH 7.4) at 2 mg/ml, loaded with cis-parinaric acid (12.8 JlM) on ice for 10 min, 
pelleted by centrifugation, washed, and resuspended at 10 mg/ml in lipid peroxidation 
buffer. Microsomes were resuspended in isolation buffer 2 at 10 mg/ml for Ca2+ uptake 
studies. Aliquots of micro somes were resuspended in 250 mM sucrose, 10 mM KCL, 10 
mM imidazole, 5 mM EDTA, 2 mM DTT, 10% glycerol at 10 mg/ml and stored at _80 0 
C, under nitrogen, until mass spectrometry analysis. 
Measurement of Microsomal Lipid Peroxidation. A fluorescent lipid, cis-parinaric 
acid, was used to measure ER lipid peroxidation as described previously [98]. Briefly, 
micro somes (400 Jlg) were added to a 96-well plate and incubated with diluent, 
inhibitors, or antioxidants at room temperature for 20 min and then treated with 200 JlM 
TBHP (final volume 0.2 ml in lipid peroxidation buffer). Membrane peroxidation was 
measured at 370 C as the loss of cis-parinaric acid fluorescence (excitation 320 nm, 
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emission 405 nm) over time using a Fluoroskan Ascent fluorescent plate reader (Thermo 
Labsystems, Franklin, MA). 
Isolation and Identification of Released Microsomal Fatty Acids. 
Thirty minutes following treatment with 200 ~M TBHP or diluent, 5 wells of each group 
were pooled and the reaction was stopped by the addition of 50 ~M butylated 
hydroxyanisole (BHA) and 0.5 ml methanol. To separate microsomes from released fatty 
acids, the reaction mixture was centrifuged at 12,000g for 20 min and supernatant 
removed. Lipids were extracted from the supernatant by the Bligh and Dyer method as 
modified by Zhang et aI., evaporated under a stream of nitrogen gas to near dryness, re-
suspended in 1 00 ~L 2: 1 chloroform:methanol, and subjected to electrospray ionization-
mass spectrometry [155-156]. 
Electrospray Ionization-Mass Spectrometry (ESI-MS). ESI-MS analysis was 
performed as described previously using a Trap XCT ion-trap mass spectrometer (Agilent 
Technologies, Santa Clara, CA) with a nitrogen drying gas flow-rate of 30 psi at 350°C 
and a nebulizer pressure of 8 L/min [116, 156]. The scanning range was from 100-2200 
mlz in the negative ion detection mode on 5 ~L of the sample scanned for 1.4 min with a 
mobile phase of acetonitrile:methanol:water (2:3:1) in 0.1% ammonium formate. Fatty 
acid species were identified according to their mlz values and confirmed using MSIMS 
analysis based on previous studies by Kerwin et aI., and Zhang et aI., [156-158]. The rnlz 
values 303, 319, 335, and 351 represent arachidonic acid species 20:4, 20:4-0H, 20:4-
OOH, and 20:4-(OH)3, respectively. Mlz values 279, 295, and 311 represent linoleic acid 
species 18:2, 18:2-0H, and 18:2-00H, respectively. For statistical analysis, rnlz values 
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and peak intensities were collected in Microsoft Excel format. The mlz values were 
truncated to the integer and data were aligned using Microsoft Access. The peak 
intensity of each species for each treatment group was compared with that of the control 
for that experiment and displayed as % control. 
Measurement of Microsomal Ca2+ Uptake and Release. The membrane impermeant 
Ca2+ sensitive probe, fluo-4 free acid, was used to measure extramicrosomal Ca2+. 
Briefly, micro somes (200 J-lg) were added to a 96 well-plate in Ca2+ uptake buffer (100 
mM KCL, 30 mM imidazole-HCI buffer, 5 mM NaN3, 20 mM ammonium oxalate, pH 
7.0, ---6 J-lM Ca2+) and incubated with diluent, inhibitors, or antioxidant at room 
temperature for 10 min [154]. Sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 
(SERCA) dependent Ca2+ uptake was initiated by the addition of 2.5 mM MgATP, 
micro somes were allowed to load 20-30 min at 37°C, and further loading was inhibited 
with thapsigargin (250 nM), a SERCA pump inhibitor. Microsomes were then treated 
with 2 mM TBHP and Fluo-4 free acid (200 nM) was added immediately prior to 
fluorescence measurements at designated timepoints (excitation 480 nm, emission 520 
nm) using a Fluoroskan Ascent fluorescent plate reader (Thermo Labsystems, Franklin, 
MA). 
Isolation of Rabbit Renal Proximal Tubule Cell (RPTC) and culture conditions. 
RPTC were isolated using the iron oxide perfusion method and grown in 35 mm tissue 
culture dishes under improved conditions as described previously [146-147]. The culture 
medium was a 1: 1 mixture of Dulbecco's modified Eagle's medium/Ham's F -12 medium 
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(without glucose, phenol red, or sodium pyruvate) supplemented with 15 mM HEPES 
buffer, 2.5 mM L-glutamine, 1 ~M pyridoxine HCI, 15 mM sodium bicarbonate, and 6 mM 
lactate. Hydrocortisone (50 nM), selenium (5 ng/ml), human transferrin (5 ~g/ml), bovine 
insulin (10 nM), and L-ascorbic acid-2-phosphate (50 ~M) were added daily to fresh 
culture medium. Confluent monolayers were subjected to treatments as described below. 
RPTC Loading and Treatment. RPTC were loaded, as previously described[159]. In 
brief, RPTC were co-loaded with 2 ~M Flu05F and 100 nM TMRM, washed, then 
incubated with 1 ~M Flu05F and 40 nM TMRM in the extracellular medium. After 
loading, RPTC were pretreated with BEL, (S)-BEL, or diluent control (DMSO) and 
incubated for 30 minutes. 
Microscopic Imaging and Analysis. RPTC were imaged, as previously described, on a 
Leica Microsystems,TCS SP2 AOBS laser scanning confocal microscope (LSCM) in an 
upright microscope configuration[159]. RPTC were treated with TBHP (500 f.lM) or 
diluent control at the start of the experiment and monitored for 1 hour. Images were 
acquired in 5-min intervals during the course of experiments. To quantify data, images 
were analyzed using Adobe Photoshop. Mean intensities of images in the green and red 
channel after background subtraction were interpreted as a quantitative measure ofER 
Ca2+ and mitochondrial membrane potential, respectively. Values are graphed as the 
percent mean intensity of each subsequent image vs. mean intensity of the image taken at 
time zero. Images comprise of 7-10 cells. 
Necrotic Cell Death. Necrotic cell death was monitored by measuring propidium iodide 
(PI) staining using flow cytometry as previously described [68, 113] . Briefly, RPTC 
were exposed to 200 f.lM TBHP or diluent (control) for 4 hrs after pretreatment with BEL 
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and/or thapsigargin for 30 min. Media was removed, cells washed, incubated in binding 
buffer (10 mM HEPES, 140 mM NaCI, 5 mM KCI, 1 mM MgCI2, 1.8 mM CaCI2, pH 
7.4) containing PI (25 Jlg/ml), and washed again in binding buffer without PI. Cells were 
then removed from the monolayer using a rubber policeman and subjected to flow 
cytometry (Becton Dickinson Facscalibur). 
Statistical Analysis. Microsomes/RPTC isolated from one rabbit represents one 
experiment (n = 1). The appropriate analysis of variance (ANOV A) was performed for 
each data set and individual means were compared using Fisher's protected least 
significant difference test with P < 0.05 being considered indicative of a statistically 
significant difference between mean values. 
Results 
The fluorescent lipid cis-parinaric acid was used to monitor oxidant-induced lipid 
peroxidation in microsomes. cis-Parinaric acid incorporates into the membrane and loses 
fluorescence when oxidized [160]. Treatment of microsomes with tert-butyl 
hydroperoxide (TBHP) caused an increased rate of lipid peroxidation compared with 
controls, and this increased rate was prevented by the addition of an antioxidant, 
butylated hydroxyanisole (BHA) (Figure 1). iPLAty is selectively sensitive to 
pharmacological inhibition by racemic BEL and enantiomer (R)-BEL but is less sensitive 
to enantiomer (S)-BEL [97, 124]. In these studies we used (S)-BEL as a negative control 
for iPLA2Y inhibition. Microsomes pretreated with (R)-BEL exhibited a greater rate of 
lipid peroxidation than TBHP alone while pretreatment with (S)-BEL (negative control) 
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had no effect (Figure 3-1). In summary, iPLAty diminished TBHP-induced ER lipid 
peroxidation. 
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Figure 3-1 (A) Effect of iPLAiY inhibition on TBHP-induced ER membrane 
peroxidation (representative). Freshly isolated rabbit kidney cortex microsomes (ER) 
were incubated with the fluorescent lipid cis-parinaric acid, washed, pretreated with 
diluent control, 16 f.lM (R)-BEL, 16 f.lM (S)-BEL, or the antioxidant BHA (50 f.lM), and 
then treated with 200 f.lM TBHP. The loss of cis-parinaric acid fluorescence (indicative of 
lipid peroxidation) was monitored over time (minutes). Results are displayed as percent 
initial fluorescence. (B) Effect of iPLAty inhibition on TBHP-induced ER membrane 
peroxidation. To determine the rate of lipid peroxidation, data was plotted as percent 
initial fluorescence for each treatment group and linear regression analysis was 
performed. Oxidation rates are displayed as percent TBHP alone. Means with different 
superscripts are significantly different from each other (P < 0.05) n=5. Values are means 
± SE. 
To determine the lipids released from microsomes during oxidative stress, we employed 
electrospray ionization-mass spectrometry (ESI-MS). The resulting ESI-Mass Spectra 
revealed that micro somes release several lipid species previously identified in the 
literature [156-158] and these species were sufficiently ionized and resolved for further 
mass spectrometric analysis (Figure 3-2A). Because we were interested in the 
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mechanism by which iPLA2y prevents lipid peroxidation, we focused on linoleic (18:2) 
and arachidonic acid (20:4) species, products of iPLAiy-mediated cleavage of 
phospholipids. TBHP caused a 1.7 -fold or greater release of arachidonic acid, linoleic 
acid, and their oxidized forms (18:2-0H, 18:2-00H, 20:4-0H, 20:4-00H, 20:4(OH)3) 
(Figures 3-2A and 3-2B). Pretreatment of microsomes with BEL prevented TBHP-
induced release of all linoleic acid species (18:2, 18:2-0H, 18:2-00H), arachidonic acid 
species 20:4 and 20:4-00H, and partially prevented the release of 20:4-0H and 
20:4(OH)3. These data provide evidence that iPLA2Y mediates oxidant-induced release of 
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Figure 3-2 (A). Representative Spectrum of Fatty Acids Released from Rabbit 
Kidney Cortex Microsomes using Electospray Ionization-Mass Spectrometry. 
Released lipids were separated from micro somes using differential centrifugation, 
extracted by Bligh Dyer method, injected directly into ESI-Mass Spectrometer, and 
analyzed in negative mode. Peaks of different mlz values represent different lipid 
species. Arachidonic Acid (20:4), Linoleic Acid (18:2) and their oxidized forms were 
confirmed by MS/MS. (B) Effect of iPLA2Y inhibition on TBHP-induced Linoleic Acid 
(18:2) Release. Microsomes were pretreated for 20 min with BEL or diluent, treated for 
30 min with 200 f.lM TBHP, and reaction was stopped and analyzed by ESI-MS. 
Linoleic Acid (18:2) and its oxidized forms (18:2-0H, 18:2-00H) were identified 
according to their mlz values and confirmed by MS/MS analysis. Results are displayed 
as peak intensity of treatment group over peak intensity of control X 100 for each lipid 
species. Means with different superscripts are significantly different from each other (P < 
0.05) n=4-6. Values are means ± SE. (C) Effect of iPLA2y inhibition on TBHP-induced 
Arachidonic Acid (20:4) Release. Microsomes were pretreated for 20 min with BEL or 
diluent, treated for 30 min with 200 f.lM TBHP, and then reaction was stopped and 
analyzed by ESI-MS. Arachidonic Acid (20:4) and its oxidized forms (20:4-0H, 20:4-
OOH, 20:4-(OH)3) were identified according to their mlz values and confirmed by 
MS/MS analysis. Results are displayed as peak intensity of treatment group over peak 
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intensity of control X 100 for each lipid species. Means with different superscripts are 
significantly different from each other (P < 0.05) n=4-6. Values are means ± SEe 
To investigate the role of iPLAiY in oxidant-induced ER Ca2+ release, we developed an 
assay to monitor ER Ca2+ uptake and release in microsomes. Fluo-4 fluorescence was 
used to monitor extra-microsomal Ca2+. A decrease in fluorescence corresponds to ER 
Ca2+ uptake while an increase represents ER Ca2+ release. The addition of A TP caused 
rapid Ca2+ uptake (loading) as indicated by a decrease in fluorescence (Figure 3-3). 
Pretreatment with thapsigargin, an inhibitor of the Sarcoplasmic/Endoplasmic Reticulum 
ATPase (SERCA), prevented the A TP dependent Ca2+ loading. The addition of 
thapsigargin at 30 min prevented further Ca2+ loading but did not cause significant Ca2+ 
release. A23187, a Ca2+ ionophore, caused rapid release of loaded Ca2+. 
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Figure 3-3. SarcoplasmiclEndoplasmic Reticulum Ca2+ ATPase (SERCA) 
de~endent calcium uptake in rabbit kidney cortex microsomes. SERCA dependent 
Ca + uptake was initiated by the addition of 2.5 mM ATP and microsomes were loaded 
with Ca2+ (ATP). As controls, microsomes were pretreated with thapsigargin (SERCA 
inhibitor) prior to ATP addition (ATP+Pre-Tg), thapsigargin was added 30 min after 
loading was initiated (ATP+ Tg), or no ATP (diluent) was added (No ATP). 200nM 
Fluo-4 salt was added immediately prior to fluorescence readings at the specified time 
points. Means with different superscripts are significantly different from each other (P < 
0.05) n=3. Values are means ± SE. 
To test whether an oxidant causes microsomal Ca2+ release and whether iPLA2Y plays a 
role in that release, we loaded microsomes with Ca2+ by adding ATP for 30 min and then 
treated with thapsigargin to prevent further loading. Microsomes were then treated with 
TBHP or diluent in the presence or absence of iPLA2y inhibition using BEL. Ca
2
+ release 
occurred approximately 50 min after treatment with TBHP and pretreatment with BEL 
potentiated the release (Figure 3-4A). Time is plotted from the addition of TBHP. 
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Pretreatment with (S)-BEL was no different than TBHP alone and antioxidant BH.A 
prevented oxidant-induced ER Ca2+ release (Figure 3-4B). In summary, iPLA2y 
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Figure 3-4 (A) Effect of iPLA2¥ inhibition on TBHP-induced Microsomal Ca
2
+ 
Release. Microsomes were pretreated at room temperature with 10 J.lM BEL or diluent 
for 10 min, loading was initiated by the addition of A TP at 37°C, and further loading was 
inhibited at 30 min by thapsigargin (Control). Microsomes were then treated with 2 mM 
TBHP in the presence (TBHP + BEL) or absence (TBHP) of BEL. Fluo-4 acid was added 
immediately prior to fluorescence readings at specified time points and results displayed 
as percent control fluorescence (microsomes loaded and treated with thapsigargin alone). 
Means with different superscripts are significantly different from each other (P < 0.05) 
n=4. Values are means ± SE. (B) The role of iPLA2y in TBHP-induced ER Ca
2
+ Release 
at 80 minutes (50 minutes after treatment with TBHP). Microsomes were pretreated with 
diluent, BEL, (S)-BEL (negative control), or BHA (antioxidant control) for 10 min at 
room temperature. Loading was initiated by the addition of 2.5 mM ATP at 37°C, 
micro somes were loaded for 30 min and then treated with diluent (ATP only group), 250 
nM thapsigargin (Control), thapsigargin and 2 mM TBHP (TBHP), or thapsigargin and 
TBHP after pretreatment with 16 J.lM BEL (TBHP+BEL), 16 J.lM (S)-BEL 
(TBHP+SBEL), or 50 J.lM BHA (TBHP+BHA). 200 nM Fluo-4 acid was added 
immediately prior to fluorescence measurements 80 minutes after the initiation of 
loading. Results were displayed as (treatment group fluorescence-ATP only group 
fluorescence)/(TBHP group fluorescence-ATP only group fluorescence) X 100). Means 
with different superscripts are significantly different from each other (P < 0.05) n=5 . 
Values are means ± SE. 
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To investigate the role of iPLA2y in oxidant-induced ER Ca
2
+ release in RPTC, cells were 
co-loaded with Flu05F, a marker of ER Ca2+, and tetramethyl rhodamine methyl ester 
(TMRM) , a marker of polarized mitochondria. Fluorescence was monitored using laser 
scanning confocal microscopy (LSCM) as previously described[159]. RPTC were 
treated with TBHP in the presence and absence of iPLA2y inhibition by BEL. Inhibition 
of iPLA2'Y prior to TBHP treatment potentiated TBHP-induced ER Ca2+ release (Fig. 5A). 
There was no significant loss of mitochondrial polarization in any group during this time 
frame (Fig. 3-5B). 




Figure 3-5. The role of iPLAty in TBHP-induced ER Ca2+ release and 
Mitochondrial Depolarization in RPTC. RPTC were loaded, as described in materials 
and methods, pretreated with BEL (5 J.!M) or diluent control for 30 min, exposed to 
TBHP (500 J.!M) or diluent control, and then monitored for 1 hr using laser scanning 
confocal microscopy. Flu05F fluorescence (green, A) and TMRM fluorescence (red, B) 
represents ER Ca2+ and mitochondrial polarization, respectively. Note, TBHP alone did 
not induce ER Ca2+ release at 30 minutes. In contrast, TBHP induced ER Ca2+ release in 
RPTC pretreated with BEL at 30 min. There were no significant changes in 
mitochondrial polarization. 
Quantification of TBHP-induced ER Ca2+ release revealed 15% and 40% ER Ca2+ release 
at 30 and 45 min, respectively, in RPTC pretreated with BEL and then exposed to TBHP. 
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In contrast, TBHP exposure alone caused no ER Ca2+ release at 30 minutes and only 20% 
release at 45 min (Fig. 3-6). Pretreatment with (S)-BEL (negative control) prior to TBHP 
exposure was no different than TBHP alone and BEL alone nor SBEL alone caused ER 
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Figure 3-6. Quantification of TBHP- induced ER Ca2+ Release in RPTC. RPTC 
were co-loaded, pretreated, exposed to TBHP, and imaged, as described in materials and 
methods. Values are mean intensities of images in the green channel ± SE and loss of 
intensity represents ER Ca2+ release. Note earlier TBHP-induced ER Ca2+ release under 
iPLAty inhibition (TBHP+BEL) compared to TBHP alone(TBHP) and negative control 
(TBHP+SBEL). BEL alone nor (S)-BEL alone caused ER Ca2+ release. 
The next experiment was designed to investigate the role of ER Ca2+ release in oxidant-
induced cell death in RPTC in the presence and absence of iPLAty inhibition. TBHP 
caused 30% necrotic cell death (propidium iodide (PI) staining) as compared to 2-3% in 
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control cells. iPLA2y inhibition with BEL prior to TBHP treatment potentiated TBHP-
induced necrotic cell death to 40% as previously reported [68, 98] (Figure 3-7). When ER 
Ca2+ was depleted with thapsigargin prior to TBHP exposure, necrotic cell death was 
reduced to 17%. Equally important, the potentiation of cell death observed when iPLA2y 
was inhibited was blocked by ER Ca2+ depletion (Figure 3-7). BEL alone and 
thapsigargin alone had no effect on cell viability. In summary, ER Ca2+ release is a major 
attributor to oxidant-induced necrotic cell death and the potentiation of cell death seen 
under iPLA2y inhibition. 
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Figure 3-7. Effect of ER Ca2+ depletion and iPLA2y inhibition on oxidant-induced 
RPTC necrosis. RPTC were treated with either diluent (DMSO), BEL, and/or 
thapsigargin for 30 min before the addition of TBHP (200 J.lM). After treatment, the 
percent PI staining was determined by flow cytometry. Means with different superscripts 
are significantly different from each other (P < 0.05) n=5. Values are means ± SE. 
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Note, the potentiation of TBHP-induced necrotic cell death by BEL, but the absence of 
potentation by BEL when ER Ca2+ stores are depleted with thapsigargin. 
Discussion 
We previously demonstrated that Ca2+ plays an important role in necrotic renal cell death 
[50, 52-53]. In 1997, we demonstrated ER Ca2+ release was a key step in necrotic cell 
death and that depletion of ER Ca2+ stores blocked death in RPTC [50]. Other studies in 
RPTC revealed that iPLAty inhibition potentiates oxidant induced lipid peroxidation and 
cell death, and knockdown of ER- iPLA2'Y correlated with increased lipid peroxidation 
and loss of cell viability [68, 98] These studies demonstrated the cytoprotective role of 
iPLA2'Y revealed the significance of ER Ca2+ release during necrotic cell death, and 
pointed to ER- iPLA2'Y in the putative lipid peroxidation repair/prevention pathway. 
However, a direct link between ER- iPLA2Y and oxidant-induced ER Ca2+ release had not 
been established, nor had the mechanism by which ER- iPLA2y is protective or is 
involved in the lipid peroxidation repair/prevention pathway been revealed. Thus, the 
goals of the present study were to understand the role of ER- iPLA2y in oxidant-induced 
ER lipid peroxidation, fatty acid release, Ca2+ release and necrotic cell death. 
We used freshly isolated rabbit kidney cortex micro somes to further investigate the role 
of ER- iPLA2Y in oxidant stress. ER- iPLA2y decreased oxidant-induced lipid 
peroxidation and Ca2+ release, and mediated oxidant-induced release of oxidized and 
unsaturated fatty acids. These results support our hypothesis that ER- iPLA2y protects 
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renal cells from oxidant injury by decreasing lipid peroxidation, ER Ca2+ release and 
subsequent necrotic cell death. These findings are consistent with our previous work in 
isolated mitochondria showing that iPLAiY protects mitochondria from oxidant-induced 
lipid peroxidation and mitochondrial swelling [98]. Also, shRNA knockdown of iPLA2y 
in RPTC increased lipid peroxidation and sensitized RPTC to nonlethal oxidant treatment 
[116]. 
It has been proposed that phospholipases playa role in membrane remodeling and repair 
during oxidant stress by cleaving oxidized and/or unsaturated fatty acids from the 
membrane, preventing the initiation and propagation of lipid peroxidation, and allowing 
for the incorporation of unoxidized fatty acids [74]. ER and mitochondria are the major 
sites of reactive oxygen species (ROS) production and the presence of iPLA2Y in 
mitochondria and ER of rabbit RPTC makes it a likely candidate for a role in membrane 
repair and remodeling. The most probable mechanism by which these enzymes prevent 
or repair lipid peroxidation is through the cleavage and removal of oxidized fatty acids 
from the membrane [81]. The initiation step of lipid peroxidation involves the 
abstraction of a hydrogen atom from the methylene carbon of a fatty acid and therefore 
fatty acids with more double bonds are more vulnerable to the initiation of lipid 
peroxidation [75]. The resulting peroxyl radical is capable of abstracting a hydrogen 
atom from adjacent fatty acids, thus propagating the lipid peroxidation and potentially 
producing several lipid hydroperoxides [76]. This chain of events can be terminated by 
the removal of the reactive lipid from the site of reaction or a chain-breaking 
antioxidant[75-77]. In our case, the inhibition of iPLA2y would result in the 
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accumulation of oxidized fatty acids in the membrane and contribute to the propagation 
of the lipid peroxidation. 
Van Kujick proposed that hydroxyl or hydroperoxyl groups introduced into fatty acyl 
chains via lipid peroxidation creates a more hydrophilic acyl chain that would move 
towards the head group of a phospholipid to become more thermodynamically stable 
[88]. This molecular rearrangement could make the ester linkage at the sn-2 position 
more accessible to PLA2 cleavage. Interestingly, both oxidized arachidonic acid and 
linoleic acid were released following exposure of ER to TBHP. While it may be true that 
oxidized fatty acids become more accessible to phospholipase cleavage, it is clear that 
iPLAl'Y is readily capable of removing non-oxidized fatty acids under oxidative 
conditions. The release of non-oxidized fatty acids, such as arachidonic acid, during 
oxidant stress raises the possibility that the non-oxidized arachidonic acid may initiate an 
inflammatory signal through one of its metabolites. This possibility requires further 
exploration. 
We developed an assay of microsomal Ca2+ release using Fluo-4, a fluorescent dye with a 
high affinity for Ca2+ (Km--- 300 nM). ATP dependent loading was consistent with 
Sheippatti et ai., in that it took approximately 20 min to reach maximal Ca2+ uptake [77, 
154]. There was little passive Ca2+ loading, as depicted in microsomes incubated 
without A TP or pretreated with thapsigargin prior to the addition of A TP. Treatment 
with thapsigargin after loading did not cause release of Ca2+ as observed in intact cells 
[50]. We used this to our advantage because we were interested in ER Ca2+ release and 
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treated microsomes with thapsigargin after loading to ensure that any Ca2+ released may 
not be re-sequestered by SERCA activity. There was not a gradual release of ER Ca2+ 
but a critical point reached approximately 50 min after treatment with TBHP. We did not 
observe ER Ca2+ release earlier under conditions of iPLA2Y inhibition, but instead we 
observed the potentiation of ER Ca2+ release 50 min after TBHP treatment. These data 
provide evidence that iPLA2Y is protective by preventing the propagation of lipid 
peroxidation. 
To investigate the role of iPLA2y in oxidant-induced RPTC ER Ca
2
+ release, we utilized 
a method developed in our laboratory of monitoring ER Ca2+ directly using low affinity 
Ca2+ indicator, Fluo5F, and laser scanning confocal microscopy. These data revealed that 
iPLA2Y inhibition resulted in oxidant-induced ER Ca2+ release at an earlier time point 
than TBHP alone. Collectively, these data support our hypothesis that ER- iPLA2y 
protects renal cells from oxidant-induced necrotic cell death by preventing ER lipid 
peroxidation, preserving ER membrane integrity, and blocking ER Ca2+ release and loss 
of Ca2+ homeostasis. 
Interestingly, iPLAiY inhibition alone was not sufficient to cause ER Ca2+ release within 
the course of the experiment. These data suggest that iPLA2y is most important under 
conditions of elevated oxidant stress such as would be experienced during 
ischemiaireperfusion or toxicant injury. Additionally, our studies in RPTC reveal that 
oxidant-induced ER Ca2+ release occurs prior to loss of mitochondrial membrane 
potential and cell death. 
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To confirm ER Ca2+ release is a mediator of oxidant-induced cell death and that iPLA2y 
plays a pivotal role in this process, we depleted the ER of Ca2+ prior to oxidant injury and 
monitored necrotic cell death in the presence and absence of iPLA2y inhibition. 
Depletion of ER Ca2+ prior to oxidant injury greatly reduced necrotic cell death and 
blocked the potentiation of cell death seen under iPLA2Y inhibition. These data reveal 
that the protection from necrotic cell death by iPLAty during oxidant injury is closely tied 
with ER Ca2+ release. This compilation of evidence supports our hypothesis that ER-
iPLA2Y is protective during oxidant injury and reveals the mechanisms by which ER 
iPLA2Y protects the ER from oxidant-induced lipid peroxidation and Ca2+ release. 
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Chapter 4 
Genetic Ablation of Ca2+ -Independent Phospholipase A2Y Induces Lipid 
Peroxidation, Oxidative DNA Damage and Loss of Phospholipid Homeostasis in 
Mouse Kidney 
Abstract 
Calcium-independent phospholipase A 2y (iPLA2y) protects primary renal cells from 
oxidant injury by preventing or repairing oxidant-induced lipid peroxidation. We tested 
this hypothesis in vivo using mice genetically ablated of iPLA2Y (KO mice) and 
investigated its role in age-related renal oxidant injury. Urinary 8-isoprostanes and 8-
hydroxy-2'-deoxyguanosine (8-0HdG), biomarkers of lipid peroxidation and oxidative 
DNA damage, respectively, increased in 13 month KO mice compared to WT mice. 
Urinary lipidomic analysis demonstrated decreases in phospholipid species 38:6, 38:5 
and 37:5 phosphatidylcholine and increases in 6-10 carbon fatty acids, with methyl or 
keto additions. Thirteen month KO mouse kidney cortex exhibited higher lipid 
peroxidation and 8-0HdG staining compared to WT mice. No differences in kidney 
function were detected between KO and WT mice at 2 or 13 months of age. Renal 
mitochondrial respiratory proteins NDUFB8 and COX-I, and mitochondrial DNA copy 
number increased in KO mice. KO mice exhibited increased mRNA levels of GPx4, an 
antioxidant enzyme that contains lipid hydroperoxidase activity. Collectively, these 
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studies reveal that genetic ablation of iPLA2y results in 1) increased renal oxidative lipid 
and DNA damage, 2) disruption of mitochondrial homeostasis with increased respiratory 
proteins and mtDNA, and 3) a compensatory increase in GPx4. These data provide 
evidence that iPLA2y is critical for the prevention or repair of lipid peroxidation in 
oxidative kidney injury. 
Introduction 
Phospholipase A2 (PLA2) enzymes hydrolyze the sn-2 ester bond of 
glycerophospholipids, producing a free fatty acid and a lysophospholipid [86]. Free fatty 
acids serve as signaling molecules and/or can be further metabolized to produce 
mediators of inflammation, cell signaling and death. For example, arachidonic acid is 
metabolized to prostaglandins, prostacyclins, thromboxanes and leukotrienes; all of 
which are major components of inflammatory and signaling pathways [87]. 
Lysophospholipids can serve as substrates for the re-esterification of free fatty acids by 
CoA-dependent acyltransferases [82]. The ability of PLA2 to release fatty acids from 
phospholipid membranes and, in tum, allow for the re-esterification of free fatty acids 
from cellular pools is the basis for its putative involvement in membrane 
remodeling/repair pathways; however, their role in these pathways have not been fully 
elucidated [88]. 
iPLA2y is one of seven Ca
2
+ -independent PLA2 and belongs to the Group VIB family. 
Our previous studies detected high levels of iPLA2y expression and activity in rabbit 
renal cells that were localized to the endoplasmic reticulum (ER) and mitochondria, the 
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major sites of reactive oxygen species (ROS) production and targets of oxidant injury 
[68, 97-98, 112]. Pharmacological inhibition of iPLA2y potentiated oxidant-induced lipid 
peroxidation in isolated mitochondria and ER, and potentiated oxidant-induced 
mitochondrial permeability transition (MPT) and ER Ca2+ release, respectively [98, 161]. 
Pharmacological inhibition of iPLA2y also potentiated lipid peroxidation and necrotic cell 
death in renal proximal tubule cells (RPTC) [68]. Recently, we showed that knockdown 
of iPLA2Y using shRNA increased several speCIes of phosphatidylcholine, 
phosphatidylethanolamine, and phosphatidylglycerol phospholipid classes [116]. 
Additionally, we demonstrated iPLA2y mediated release of oxidized and non-oxidized 
fatty acids from the ER during oxidative stress [161]. These data provide strong evidence 
that iPLA2Y is a major component of the membrane remodeling/repair pathway and is 
thereby protective during oxidant stress in renal cells. 
Mancuso et al. generated mice null for iPLA2y by genetically ablating the enzyme's 
active site [136]. These mice were more vulnerable to cardiac stress (transverse aortic 
constriction), were resistant to high fat diet-induced weight gain, exhibited cognitive 
dysfunction and exhibited multiple dysfunctional bio-energetic phenotypes, such as cold 
intolerance and reduced exercise endurance, compared to their wild type liter mates [134-
136]. Interestingly, Yoda et ai. also generated mice null of iPLA2Y and reported 
increased lipid peroxidation in skeletal muscle, and, similarly to the work of Mancuso et 
aI., alterations in cardiolipin content and mitochondrial dysfunction [141]. Together, 
these data support our previous findings that impairment of iPLA2Y increases oxidative 
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stress, alters lipid homeostasis, and increases mitochondrial dysfunction in vitro. The 
effects of knocking out iPLAty in the kidney have not been studied. 
The goal of these studies was to examine the consequences of iPLA2y loss in the kidney, 
particularly with respect to age. Because oxidant stress is a major component of age-
related deterioration of kidney function and iPLA2y protects RPTC from oxidative stress, 
we hypothesized that mice genetically ablated of iPLA2Y will have increased levels of 
oxidative stress and display altered lipid homeostasis, and that these changes will be more 
apparent as mice age. 
Experimental Procedures 
Mouse Husbandry 
Mice of a mixed genetic background of C57BL/6 x 129/Sv with the region encoding the 
active site of the iPLA2y removed [136] were a gift from Dr. Richard Gross at 
Washington University School of Medicine, St. Louis, MO. Mice were housed In 
standard animal rooms under normal conditions: 12 hr dark (18.00-06.00 hr)-12 hr 
artificial light (06.00-18.00 hr) cycle; temperature maintained at 21 ± 1°C; and relative 
humidity varied between 30 and 60% and received food and water ad libitum. 
Heterozygous mice were bred under pathogen-free conditions and the resulting WT and 
KO male mice were used for these studies. PCR analysis was performed for genotyping, 
as previously described [136]. All studies were reviewed and approved by the 
institutional animal care and use committee of the Medical University of South Carolina 
85 
and were in accordance with the National Institutes of Health guidelines for humane 
treatment of animals. 
Urine and Tissue Collection 
For 24 hr urine collection, mice were weighed, and then housed individually in metabolic 
cages. Urine samples were centrifuged at 800 g for 5 min, supernatant volume measured 
and antioxidant (BHT, 0.05%) added. Samples were either analyzed immediately or 
aliquoted and frozen at -80°C for further analysis. Mice were then euthanized by 
intraperitoneal injection of pentobarbital, blood taken via cardiac puncture, and kidneys 
collected for tissue analysis. A portion of the kidney was fixed in 10% buffered formalin 
for greater than 24 hr and subsequently processed for histology or 
immunohistochemistry. The remaining kidney tissue was stored at -80°C. Serum was 
separated from whole blood by standard methods, BHT added, and was either used 
immediately or stored at -80°C. 
Urine and Serum Assays 
Urine and serum creatinine were measured using a QuantiChrom Creatinine Assay Kit 
according to the manufacturer's protocol (Hayward, CA). Each sample was tested in 
duplicate and values expressed in mg/dl. 8-isoprostane and 8-0HdG were measured in 
urine using ELISA assay kits as markers of lipid peroxidation and oxidative DNA 
damage, respectively (Cayman Chemicals, Ann Arbor, MI). Generally, samples were 
diluted 1 :20 and 1: 1000 for 8-isoprostane and 8-0HdG, respectively. 
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Histology 
Renal tissues were fixed in 10% buffered formalin, dehydrated, and embedded in 
paraffin. For general histology, sections were stained with hematoxylin/eosin or PAS and 
were scored in a blinded fashion by a renal pathologist, Dr. Judit Megyesi, University of 
Arkansas for Medical Sciences. Briefly, morphologic damage (tubular necrosis, loss of 
brush border, casts, inflammatory cells, tubular dilatation, distal damage, degeneration, 
red blood cell extravazation, interstitial edema, glomerular changes, and interstitial 
fibrotic foci) of the entire kidney section was scored semi quantitatively using the 
following scale: none= 0; <10%= 1; 11-250/0= 2; 26-75%== 3; and 75%== 4. 
Immunohistochemistry 
Slides were emersed twice in xylene for 5 min and were dehydrated by emersion in 
100%, 95% and 70% histological grade ethanol, consecutively, for 6 min each. Slides 
were rinsed in PBS, incubated in 30% H202 for 30 min, and then incubated in 2% normal 
horse serum for 20 min to block non-specific binding. Slides were washed twice with 
PBS and incubated with primary antibodies against 8-0HdG (9.75 ~g/ml) for 18 hours. 
Slides were washed three times in PBS for 5 min, incubated for 30 min in PBS containing 
a universal secondary antibody and Elite Reagent (Vector labs; Burlingame, CA, USA), 
and then incubated for 30 min with DAB reagent and Gills Hematoxylin, as a counter 
stain. Slides were bathed in ammonium hydroxide (10% V/v) , dehydrated, and 
fluoromount and cover slips were applied. Images were taken using a Nikon AZI00 
fluorescence microscope and positively stained nuclei per field were counted from three 
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random images (25X) in a double blinded fashion. 8-0HdG antibody was purchased 
from Rockland Immunochemicals (Gilbertsville, PA, USA). 
Tissue Lipid Peroxidation Assay 
To measure thiobarbituric acid reacting substances (TBARS), mouse kidney cortex (-----25 
mg) was placed in 500 f.ll RIPA Buffer (50 mM Tris-HCL, 150 mM NaCI, 1 % Triton X-
100, 1 % Sodium Deoxycholate, 0.1 % SDS, 1 mM EDT A) containing protease inhibitors 
and BHT (0.05%) and sonicated on ice for 15 sec at 1400 V. An aliquot (50 J-lI) was 
taken for protein quantification. Samples were centrifuged at 1600 g for 10 min at 4°C 
and supernatant used for the assay. Color reagent containing 200 f.ll 8.1 % SDS, 1.5 ml 
20% acetic acid (pH=3.5), 1.5 ml 0.8% thiobarbituric acid, and 700 f.ll water was added 
vigorously to 100 f.ll sample (supernatant) in a glass vial and boiled for 1 hr at 95°C. To 
stop the reaction, the mixture was placed on ice for 10 min, then centrifuged at 3000 g for 
10 min. A 200 ul aliquot of supernatant was taken and absorbance measured at 650 nm. 
1, 1, 3, 3-Tetraethoxy-propane was used as a standard. Methods were modified from 
Ohkawa et al. [162]. 
Bligh-Dyer lipid extraction 
Urine lipids were extracted using chloroform and methanol according to the method of 
Bligh and Dyer [155]. Urine (1 mL) was mixed with 2 mL methanol: water (2.0:0.8 v/v), 
transferred to a glass test tube, 1.25 ml chloroform was added, and tubes were vortexed 
for 30 sec and allowed to sit for 10 min on ice. Tubes were centrifuged at 213 g for 1 
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min and the bottom chloroform layer was transferred to a new test tube. The extraction 
steps were repeated and the chloroform layers combined. The collected chloroform 
layers were dried under argon, reconstituted with 50 JlL of methanol:chloroform (2:1 
v/v), and stored at -20°C. 
Lipid phosphorus assay 
Lipid phosphorus was quantified using a modified Bartlett inorganic phosphorous assay 
[163]. Lipid extract (10 JlL) was mixed with 400 JlL of ION sulfuric acid and heated at 
180-200°C for 1 hr in a glass test tube. After this time, 100 JlL of 30% hydrogen 
peroxide was added while vortexing and the tube was heated for an additional 1.5 hr. 
The tube was removed from heat and 4.6 mL of molybdate reagent and 100 JlL of 15% 
ascorbic acid were added consecutively while vortexing. Samples were then placed in a 
boiling water bath for 10 min before absorbance was read at 825 nm. 
Characterization and quantitation of urinary lipids using electrospray ionization-
mass spectrometry (ESIIMS). 
Lipid extract samples (20 pmol/JlI) were prepared by reconstituting in chloroform: 
methanol (2: 1, v/v). Samples were analyzed using an Agilent Trap XCT ion-trap mass 
spectrometer equipped with an electrospray ion source (Agilent, Santa Clara, CA). 
Samples (5 ilL) were introduced by means of a flow injector into the ESI chamber at a 
rate of 0.2 mL/min. The elution solvent was acetonitrile:methanol:water (2:3: 1, v/v/v) 
containing 0.1 % (w/v) ammonium formate (pH 6.4). The mass spectrometer was 
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operated in both positive and negative scanning mode. The flow rate of nitrogen drying 
gas was 8 Llmin at 350°C. The capillary and cone voltages were set at 2.5 kV and 30 V 
respectively. Qualitative identification of individual phospholipid and fatty acid species 
was based on their calculated theoretical monoisotopic mass values, followed by a 
subsequent round of MS to identify fragmentation products (MS/MS). Relative 
abundance was determined by comparison to the total ion count in each sample. 
Immunoblot Analysis 
Approximately 25 mg of frozen kidney tissues were homogenized and disrupted by 
sonication for 30 sec using homogenization buffer supplemented with protease inhibitors. 
Equal amounts of tissue homogenates were separated by SDS-PAGE and 
electrophoretically transferred to nitrocellulose membranes. After treatment with 5% 
skim milk for 1 hr at room temperature, membranes were incubated with various 
antibodies NDUFB8 & COX I (Invitrogen, Carlsbad, CA ), A TP Synthase ~ (Abeam, 
Cambridge, MA) and GAPDH (Fitzgerald, Concord, MA) overnight at 4°C and then 
incubated with an appropriate horseradish peroxidase-conjugated secondary antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hr at room temperature. Bound 
antibodies were visualized after chemiluminescence detection on an AlphaEase FC stand-
alone imaging system (San Leandro, CA). 
Mitochondrial DNA Copy Number 
Real-time PCR was used to determine relative quantities of mitochondrial DNA content 
in WT and KO animal kidney tissues. Total genomic DNA was extracted using a DNeasy 
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Blood and Tissue kit (QIAGEN, Valencia, CA). DNA was quantified by measuring A260 
values and 50 ng of total DNA was used for PCR, as previously described [164]. Primers 
specific to the mitochondrial-encoded ND6 gene were used to assess mitochondrial DNA 
copy numbers. Primers designed against the nuclear-encoded tubulin gene were used for 
normalization and are listed in Table 4-1. 
Gene Sequence 
GPx4 FW: TGT GCA TCCC GCG ATG A TT 
REV: CCC TGTACT TAT CCA GGC AGA 
GR· 1 FW: GAC ACC TCT TCC TTC GAC TAC C 
REV: CCC AGC TTG TGA eTC TCC AC 
ND6 FW: AGG GCTTGG GTTGATTGTTAG 
REV: TGC CAT CGC AGTAGT ATA CCC 
Prdx6 FW: CAT CCG CTTCCA eGA TTTCCT 
REV: eTC TGC CAA GTT CTG TGG TG 
Tubu/in FW: CTC TCT GTC GAT TAC GGC AAG 
REV: TGG TGA GGA TGG AGT TGT AGG 
Table 4-1. Primers used for qRT-PCR experiments 
Quantitative Real-Time PCR 
Total RNA was isolated from kidney tissues with TRIzol reagent (Invitrogen). cDNA 
was synthesized from 1 l-lg of RNA template using a RevertAid™ First Strand cDNA 
Synthesis Kit (Fermentas Inc., Glen Bernie, MD). PCR was carried out, as previously 
described [19], using 3 f.ll of 1:3 diluted cDNA template combined with Maxima® SYBR 
Green qPCR Master Mix (2X) at a final concentration of IX (Fermentas Inc.), ROX 
(Fermentas Inc.) and primers (Invitrogen, Carlsbad, CA) at a concentration of 10 nM and 
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400 nM respectively. Sequences of primers used for real-time PCRs are listed in Table 4-
1. 
Statistical Analysis 
Tissues isolated from one mouse represents N = 1. The appropriate analysis of variance 
(ANOVA) was performed for each data set and individual means were compared using 
Fisher's protected least significant difference test with P < 0.05 being considered 
indicative of a statistically significant difference between mean values. 
Results 
Male KO mice appeared normal at birth and exhibited normal ambulatory activity as 
previously described [136]. To assess general phenotypic features of KO mice, we 
measured age-related differences in weight (Table 4-2). There were no significant 
differences in weight between male KO and WT mice at 2 months; however, KO mice 
did not gain weight after 2 months of age. KO mice were --55% the weight of WT mice 
at 13 months. KO mice at 13 months of age began to show kyphosis and reduced 
ambulatory activity. These findings are consistent with previous reports [136, 141]. 
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2 months 13 months 
WT KO WT KO 
Weight (g) 21 i 1 20 ± 1 47:1:1 23 t 1* 
Serum Creatinine (mg/dl) 0.32:!: 0.1 0.36 ± 0.1 0.33 :I: 0.1 0.37 ± 0.1 
Urine Volume 90 :!: 25 78 :t 11 20:1: 1 21 ± 1 
(m1/24 hr)/kg 
Urine Creatinine 675 ±112 595 :1:85 815 t 145 940 t 151 
(mg/ml)/kg 
Creatinine Clearance 2.8 :to.8 2.0:1:0.6 2.0 ± 0.6 1.7 ± 0.5 
(ml/min)/kg 
Table 4-2. General age-related phenotypic features and kidney function of iPLA2y -
/- mice Weight and serum creatinine were measured. Mice were placed in metabolic 
cages for 24 hrs and urine volume and urinary creatinine were measured and corrected for 
weight. Creatinine clearance was calculated. Values are means ± SE in the units 
designated. Means highlighted with an asterisk denotes mean of KO animals is 
significantly different from mean ofWT animals within the age group (N=4-8) p<O.05. 
To assess the effects of genetic ablation of iPLA2y on kidney function, we measured 
serum and urine creatinine, urine volume and calculated creatinine clearance. There were 
no significant differences in these parameters between WT and KO animals at 2 or 13 
months when standardized to body weight (Table 4-2). In summary, KO mice did not 
display overt changes in renal function. 
Kidney histology was evaluated for tubular necrOSIS, loss of brush border, casts, 
inflammatory cells, tubular dilatation, distal tubule damage, degeneration, red blood cell 
extravasation, interstitial edema, glomerular changes, and interstitial fibrotic foci. 
Kidney cortex from 2 month old KO mice exhibited tubular degeneration and loss of 
93 
brush border compared to 2 month WT controls (Fig. 4-1, Table 4-3). Kidney tissues 
from 13 month WT controls exhibited increased markers of the aging kidney (i.e. loss of 
brush border, tubular dilatation and degeneration, glomerular changes, and interstitial 
fibrotic foci). KO mice exhibited similar age-related histological changes except tubular 
dilatation was decreased in 13 month iPLA2y KO animals compared to 13 month WT 
controls. In summary, while genetic ablation of iPLA2y resulted in some changes of 
kidney morphology at 2 months of age compared to WT mice, kidney morphology at 13 
months of age was not markedly different between KO and WT mice. 
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Figure 4-1. Effects of iPLA2'Y -/- ablation and aging on mice kidney histology. 
Periodic Acid/Schiff reagent (PAS) stained sections of 2 and 13 month old iPLAiY KO 
and WT mouse kidney at 40X magnification. Tubules highlighted with an asterisk exhibit 
loss of brush border and tubular degeneration. Regions outlined in blue exhibit 
interstitial fibrotic foci. 
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2 months 13 months 
WT KO WT KO 
Tubular Necrosis 0:1:0 1.3 ±0.8 O±O 0:1:0 
Loss of Brush Border 0.2 ± 0.2 2.5 :I: 0.5· 3.3f 0.2 3.0 :1:0.4 
Casts 0:1:0 1.3 :I: 0.8 1.5:!: 0.2 0.8:1:0.2 
Inflammatory Cells 1.0 :I: 0.5 2.2 :1:0.5 2.5:1:0.2 2.5:1:0.3 
Tubular Dilatation 0:1:0 0.7 :1:0.5 2.0 :1:0.3 0.6 ± 0.4* 
Distal Damage O:tO 1.1 :I: 0.7 0.2fO.2 0.4:1:0.2 
Degeneration 0.5:1:0.5 2.3 :to.6* 3.5:1:0.2 3.0±0.2 
Red Blood Cell Extravazation 1.0 f 0.4 2.5 :1:0.4 1.5:1: 0.2 1.8 :I: 0.5 
Interstitial Edema 0:1:0 0.2:1:0.2 Of 0 0:1:0 
Glomerular Changes 0:1:0 Of 0 2.3:tO.2 2.4:1: 0.2 
Interstitial Fibrotic Foci 0:1:0 0:1:0 1.9:1:0.2 1.6 :I: 0.2 
Table 4-3. iPLA2y -/- mice kidney histology and aging. Histological sections of 2 and 
13 month iPLA2y KO and WT mouse kidney sections were stained with 
hematoxylin/eosin or PAS and scored in a blinded fashion by a renal pathologist. 
Morphological damage in 10-12 fields per section were quantified using the following 
scale: none= 0; <10%= 1; 11-25%= 2; 26-75%= 3; and 75%= 4. Values are mean scores 
± SE. Means highlighted with an asterisk denotes mean of KO animals is significantly 
different from mean of WT animals within the age group. 
To investigate the effects of genetic ablation of iPLA2y on oxidant injury in vivo, we 
measured urinary 8-isoprostanes and 8-hydroxy-2' -deoxyguanosine (8-0HdG), 
biomarkers of lipid. peroxidation and oxidative DNA damage, respectively. Because 
there was no change in serum creatinine, and as creatinine excretion correlated with 
weight, we normalized the data to urinary creatinine concentration within each sample. 
There were no differences in urinary 8-isoprostanes or 8-0HdG concentrations in KO and 
WT mice at 2 months of age (Fig. 4-2). However, 13 month KO mice excreted 9-fold 
higher 8-isoprostane and 2-fold higher 8-0HdG compared to 13 month WT mice. In 
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summary, genetic ablation of iPLA2y increased markers of lipid peroxidation and 
oxidative DNA damage in the urine. 
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Figure 4-2. Increased urinary markers of oxidative stress and oxidative DNA damage in 
aged iPLA2y -/- mice. Urine was collected for 24 hr from 2 and 13 month old male iPLA2y KO 
and WT mice. Urinary 8-isoprostanes (A) and 8-0HdG (B), markers of oxidative stress and 
oxidative DNA damage respectively, were quantified using an ELISA assay kit and normalized to 
urine creatinine. Values are mean (pg/mg creatinine) ± SE for 8-isoprostanes and mean (ng/mg 
creatinine) ± SE for 8-0HdG. Means highlighted with an asterisk denotes that the mean of KO 
animals is significantly different from the mean of WT animals within the age group (N=3-7, p< 
0.05). 
To assess kidney specific oxidative DNA damage, we stained the kidney tissue for 8-
OHdG"'using immunohistochemistry. There was a 2-fold increase in 8-0HdG staining in 
KO mice at 2 and 13 months compared to WT age-matched control animals (Fig. 4-3A 
and B, and Fig. 4-4). Interestingly, 8-0HdG staining was more pronounced in the cortex 
and proximal tubules with little evidence of 8-0HdG staining in glomeruli. 
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A B 
2 months 13 months 
Figure 4-3. Kidney specific oxidant injury in iPLA2Y -/- mouse kidney cortex. 
Increased oxidative DNA damage. Immunohistochemistry using an antibody specific to 
8-hydroxy-2'-deoxyguanosine (8-0HdG) was performed on sections of 2 month old (A) 
and 13 month old (B) iPLA2y WT and KO mouse kidney cortex. "G" denotes glomeruli 
and arrows point to 8-0HdG stained nuclei. Note: nuclei stained for 8-0HdG are present 
mostly in proximal tubule segments and not in glomeruli. 
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Figure 4-4. Quantification of nuclei stained for 8-0HdG. Darkly stained nuclei were 
counted per field in a double-blinded fashion on sections of 2 and 13 month iPLA2y WT 
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and KO mouse kidney cortex. Data are expressed as stained nuclei per field (25X) and 
are presented as means ± SEM. 
We measured thiobarbituric acid reacting speCIes (TBARS), a marker of lipid 
peroxidation, in mouse kidney cortex. There were no differences in TBARS formation 
in KO and WT kidney cortex at 2 months of age. However, kidney cortex of 13 month 






Figure 4-5. Increased lipid peroxidation (TBARS). Kidney cortex of 2 and 13 month 
male iPLA2y WT and KO mice were isolated and thiobarbituric acid reacting species 
(TBARS) were measured as described in Materials and Methods section. Data (nmol/g 
wet kidney cortex) are presented as mean ± SEM. Means highlighted with an asterisk 
denotes that the mean of KO animals is significantly different from the mean of WT 
animals within the age group. 
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To assess the effects of genetic ablation of iPLA2Y on lipid homeostasis, we performed 
lipidomic analysis of urine from 13 month old WT and KO mice using ESI-MS/MS. The 
intensities of phospholipid species with mlz values of 790.6, 792.5 and 794.4 were 
decreased in KO mice compared to WT controls and were identified as 38:6, 38:5 and 
37:5 phosphatidylcholine, respectively (Fig. 4-6). Analysis of urine fatty acid using ESI-
MS revealed no changes in "palmitic, linoleic, stearic or arachidonic acid between 13 
month WT and KO mice urine (data not shown). However, there were significant 
increases in intensities at mlz values of 128.7, 143.7 and 178.4 in KO mice urine 
compared to WT controls (Fig. 4-6). Analysis using Lipid Maps (www.lipidmaps.org) 
and subsequent MS (ESI-MS/MS) suggested that these species are fatty acids contain 6-
10 carbons with methyl or keto additions. In summary, genetic ablation of iPLA2Y 
decreased phosphatidylcholine species and increased fatty acids with methyl or keto 
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Figure 4-6. Effect of genetic ablation of iPLAty on phospholipid and fatty acid 
homeostasis in mice urine. Urine was collected for 24 hr from 13 month old male 
iPLA2¥ KO and WT mice and analyzed for phospholipids and fatty acids using ESI-MS. 
Data are normalized to total ion count and mlz are those identified in the negative (128.7, 
147.7 and 178.4) and positive (790.6, 792.5 and 794.4) modes. The identities for these 
lipids are indicated in the graph and are based on theoretical m/z value in Lipid Maps 
(www.lipidmaps.org) and subsequent MS/MS analysis. Data are presented as the means 
± SD of 3-6 separate mice and means highlighted with an asterisk denotes a significant 
difference from WT animals. 
To assess the effect of genetic ablation of iPLA2¥ on mitochondrial respiratory enzymes, 
we measured protein levels of NDUFB8 (Complex I), COX-1 (Complex IV), and ATP 
synthase ~ (Complex V) of the electron transport chain (ETC). ATP Synthase ~ and 
NDUFB8 are nuclear encoded, while COX-1 is mitochondrial encoded. There was a 1.5-
fold increase in NDUFB8 protein expression in KO mice kidney cortex in 2 and 13 
month animals compared to 2 month WT controls (Fig. 4-7A and B). COX-1 protein 
101 
expression increased by 50% in KO mice kidney cortex at 2 months compared to controls 
and trended to increase at 13 months. In contrast, A TP synthase ~ protein expression 
decreased by '"'-'50% in 2 month KO animals compared to 2 month controls, but returned 
to control levels at 13 months. In summary, genetic ablation of iPLA2y increased the 
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Figure 4-7. Effect of genetic ablation of iPLAty on mitochondrial respiratory 
proteins in 2 and 13 month old mice kidneys. (A) Expression of mitochondrial 
respiratory proteins (NDUFB8, COX-I, and ATP Synthase ~) in kidney cortex of 2 and 
13 months old male iPLA2y KO and WT mice was examined by immunoblot analysis 
(representative). (B) Data were normalized by GAPDH protein expression (internal 
control) and presented as mean ± SEM fold change over control (2 month WT animals). 
Bars with different superscripts are significantly different from each other (N = 3-7, 
p<0.05). 
Oxidative stress and subsequent loss of mitochondrial function, reduced mitochondrial 
efficiency, and increased mitochondrial DNA (mtDNA) damage and mutation are 
believed to be major components of aging [165]. We used real-time PCR to assess the 
effect of genetic ablation of iPLA2y and aging on kidney cortex mtDNA copy number. 
Mitochondrial copy number increased with age and KO mice exhibited greater 
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mitochondrial copy numbers than WT mice at 2 month; this trend was sustained at 13 
months (Fig. 4-8). 






Figure 4-8. Increased mitochondrial copy number in aged iPLAty -/- mice kidney 
cortex. DNA was isolated from kidney cortex of 2 and 13 month old male iPLA2y KO 
and WT mice and analyzed by real-time peR for relative quantities of mitochondrial-
encoded ND6 gene and normalized to nuclear-encoded tubulin gene. Data are presented 
as the means ± SEM fold change over control (2 month WT animals). Bars with different 
superscripts are significantly different from each other (N = 3-7, p<0.05). 
Upregulation of antioxidant enzyme stress response pathways are believed to be a 
compensatory mechanism by which cellular systems maintain function and viability 
during aging and increased oxidant stress, and mRNA levels of antioxidant enzymes are 
markers of oxidant stress response in the kidney [166-168]. Glutathione peroxidase 4 
(GPx4), a phospholipid hydroperoxidase, and peroxiredoxin 6 (Prdx6), a member of 
thiol-specific antioxidant enzyme family with both glutathione peroxidase and 
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phospholipase A2 activity, are antioxidant enzymes that reduce lipid hydroperoxides and 
are thought to play a role in lipid peroxidation-induced oxidant stress response and 
regulation of phospholipid turnover [169-171]. Glutathione reductase 1 (GR1) converts 
oxidized glutathione to glutathione but does not have lipid hydroperoxidase activity 
[172]. To assess the antioxidant enzyme stress response following iPLA2y ablation, we 
measured mRNA expression of these enzymes in WT and KO animals at 2 and 13 
months of age using real-time PCR (Fig. 4-9). There was a 3-fold increase in GPx4 
mRNA expression in 2 month iPLA2Y KO mice compared to 2 month control animals 
(Fig.4-9A). At 13 months, there was a 2-fold increase in both KO and WT mice GPx4 
mRNA expression compared to 2 month WT controls. Conversely, Prdx6 mRNA 
expression decreased by 60% in 2 month KO mice compared to 2 month controls (Fig. 4-
9B). There were no differences in Prdx6 mRNA levels between 13 month KO and 
control mice, and these levels were similar to those observed in 2 month controls. There 
were no differences in GRI mRNA levels between KO and WT mice at either age (Fig. 
4-9C). In summary, genetic ablation of iPLA2y resulted in a compensatory increase in 











Figure 4-9. Effect of genetic ablation of iPLA2y on antioxidant stress response proteins 
mRNA expression in 2 and 13 month old mice kidney cortex. mRNA was isolated from 2 and 
13 month old male iPLA2y KO and WT mice kidney cortex and analyzed by real-time peR for 
relative quantities of (A) Glutathione Peroxidase 4 (GPx4), (B) Peroxiredoxin 6 (Prdx6) and (C) 
Glutathione Reduction 1 (GR1). Data were normalized to tubulin mRNA expression (internal 
control) and presented as mean ± SEM fold change over control (2 month WT animals). Bars 
with different superscripts are significantly different from each other (N = 3-7, p<O.05). 
Discussion 
We previously demonstrated in primary cultures of renal cells that pharmacological 




mitochondrial permeability transition, and renal cell death [68, 97-98, 161]. Genetic 
ablation of iPLA2y using shRNA resulted in increased lipid peroxidation, loss of cell 
viability, and increased vulnerability to oxidant stress in renal cells [116]. These studies 
revealed the protective role of iPLA2y in renal cells and implicated the enzyme in 
putative membrane remodeling/repair pathways. 
Mancuso et al. showed increased susceptibility to cardiac stress, cognitive dysfunction, 
mitochondrial dysfunction (heart, brain, and skeletal muscle) and loss of lipid 
homeostasis in mice null for iPLA2y, and Y oda et al. showed increased lipid 
peroxidation, loss of lipid homeostasis, mitochondrial dysfunction, and induction of 
oxidant-stress related proteins in skeletal muscle [134-136, 141]. Together, these 
findings support our previous data revealing iPLA2y as a protective enzyme of oxidative 
stress, and provide evidence that impairment of iPLA2y in vivo results in increased 
oxidant stress, mitochondrial dysfunction, and organ dysfunction. Because oxidant injury 
is a major component of age-related loss of kidney function, the goal of the present study 
was to elucidate the role of iPLA2Y in age-related renal oxidant injury. 
To determine if genetic ablation of iPLA2y resulted in age-related loss of kidney function, 
several parameters of kidney function were monitored, including serum creatinine 
concentration and urinary creatinine clearance. Genetic ablation of iPLA2y was not 
sufficient to decrease these clinical markers of kidney function. However, creatinine 
measurements have inherent limitations in measuring kidney function and more sensitive 
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measures of kidney function have long-been sought [173]. Urinary NGAL, although a 
more sensitive measurement of acute kidney injury [174], is not an effective marker of 
chronic kidney injury or impairment [175], and there were no age or phenotype related 
changes in urinary NGAL excretion (data not shown). However, the absence of increased 
NGAL excretion should be interpreted cautiously [176]. 
Despite no changes in clinical markers of kidney function in young and aged mice, 
kidney histology in 2 month old mice exhibited loss of brush border and tubular 
degeneration. These findings are suggestive of tubular dysfunction in 2 month old 
iPLA2y ablated mice that is not sufficient to overcome the reserve capacity of the kidney. 
Similarly, greater than a 50% loss of function of kidney cortical tissue is often necessary 
to lead to clinical markers of kidney dysfunction in humans, such as increased serum 
creatinine [173]. Interestingly, there were no remarkable differences in gross histology 
between KO and WT animals at 13 months, which suggests a compensatory response and 
recovery of tubular structure. Similarly, genetic ablation of iPLA2Y in the brain also 
showed no differences between KO and WT animals in H&E staining in aged animals, 
but immunohistochemistry revealed small ubiquitin-positive inclusions suggesting 
pathology. 
Our in vitro studies using renal cells revealed that iPLA2Y loss results in oxidant injury 
(5-10). Here, we show that genetic ablation of iPLA2y results in kidney oxidant stress in 
vivo. Lipid metabolites in the blood and urine, such as 8-isoprostanes, are markers of 
oxidative stress [1 77] and excretion of 8-isoprostanes was increased in aged iPLA2Y KO 
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animals. 8-isoprostane is a prostaglandin-F2-like compound produced by free radical-
catalyzed peroxidation of arachidonic acid in vivo. Additionally, iPLA2y KO animals 
exhibited increased kidney cortex lipid peroxidation as measured by TBARS assay, 
revealing kidney specific oxidant injury. To our knowledge, these data are the first to 
reveal genetic ablation of iPLA2Y results in kidney lipid peroxidation in vivo. 
To further characterize iPLA2y-induced oxidant injury in the kidney, we stained for 8-
OHdG. 8-0HdG is a marker of oxidative DNA damage and oxidative stress and can be 
measured in serum, urine, and tissue [112, 178]. Unbound 8-0H dG is freely filtered by 
the kidney and accumulates in the urine. Organs with limited cell turnover, such as 
kidney, heart, brain, and liver, accumulate 8-0HdG with oxidant injury, and 8-0HdG in 
the urine is proportional to 8-0HdG levels in the tissues and reflects multi-organ 
oxidative DNA damage. The increase in 8-0HdG excretion in aged iPLA2¥ KO animals 
suggests increased oxidant injury. This hypothesis is supported by the increase in 8-
OHdG staining in the kidney cortex of aged iPLA2¥ KO animals. These data reveal that 
genetic ablation of iPLA2Y results in both lipid peroxidation and oxidative DNA damage 
in mouse kidney cortex. 
Our in vitro studies in renal cells revealed that iPLA2Y mediates fatty acid release and 
maintenance of phospholipid homeostasis during oxidative stress [113, 116, 161]. In this 
study, we measured urinary levels of phospholipids and fatty acids. While few 
phospholipid species were identified in mouse urine, phospholipid species (38:6, 38:5 
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and 37:5 phosphatidylcholine) were decreased in iPLA2y KO animals compared to 
controls. These data provide evidence that these phospholipids may be the downstream 
targets of iPLA2y ablation-induced oxidative stress, substrates of iPLA2y activity, and/or 
are the result of iPLA2y-mediated phospholipid repair. Similarly, our previous studies 
revealed that iPLA2Y knockdown increased only a few phospholipids (one 
phosphatidylcholine) in renal cells out of the 267 mlz values studied [116], and inhibition 
of iPLA2y in isolated mitochondrial and ER prevented the release of plasmenylcholine 
and phosphatidylcholine substrates [98]. 
The 6-10 carbon fatty acids with methyl or keto additions, increased in iPLA2y KO 
animals, likely represent lipid peroxides or oxidized fatty acids. This finding agrees with 
our previous studies in micro somes, which showed that oxidant stress increased the 
release of unsaturated andlor oxidized fatty acids and iPLA2y mediated their release 
[161]. These findings provide strong evidence that genetic ablation of iPLA2Y leads to 
alterations in fatty acid and phospholipid homeostasis. Together, these findings, along 
with increased urinary 8-isoprostanes and increased TBARS content in kidney cortex of 
iPLA2y KO animals, provide evidence that genetic ablation of iPLA2y results in lipid 
peroxidation in vivo in the kidney. 
Mitochondria are both producers and targets of oxidative stress. Protein analysis revealed 
that iPLA2y ablation induced changes in renal mitochondrial respiratory proteins (ATP 
synthase ~, NDUFB8, and COX1). These changes likely reflect a compensatory 
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response to oxidative stress to maintain cell and tissue viability. NDUFB8 and COX-I are 
components of Complex I and IV, respectively, and oxidant-induced dysfunction of these 
enzymes can result in electron leak leading to the formation of superoxide radicals and 
further ROS production [179-180]. In contrast, ATP synthase p (Complex V) couples 02 
consumption by the electron transport chain with ADP phosphorylation [179]. 
Interestingly, both NDUFB8 and COX-I proteins and mtDNA copy number are 
increased, or trend to increase, in iPLA2Y KO mice compared to control animals. 
Increased NDUFB8, COX-I, and mtDNA copy number, may reflect a compensatory 
increase in mitochondrial number andlor recovery of function necessary to maintain cell 
and tissue viability[165]. 
In contrast to NDUFB8 and COX-I, ATP synthase p protein expression decreased in 2 
month KO mice, but recovered at 13 months in KO animals. The reason for this decrease 
at 2 months is not clear. It may be the result of direct damage, or a compensatory 
response to reduce ATP production in the presence of increased NDUFB8, COX-I and 
mtDNA. Mancuso et al. demonstrated inefficient Complex IV O2 reduction suggesting 
mitochondrial dysfunction in cardiac mitochondria of 4-6 month old KO animals, 
supporting this hypothesis. Return of A TP synthase ~ protein levels and sustained 
increases in Complex I and IV enzymes in 13 month KO animals is suggestive of an 
adequate compensatory response to maintain A TP production capacity and therefore 
tissue viability. Regardless, these findings provide strong evidence that iPLA2y ablation-
induced oxidant injury disrupts electron transport chain complexes and results in a 
compensatory response. 
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Several other compensatory pathways are required to maintain cellular viability under 
oxidant stress such as the upregulation of antioxidant enzyme stress response pathways 
[166]. The increase in GPx4 mRNA in iPLAty KO mice supports the conclusion that 
genetic ablation of iPLA2y induces a compensatory response in antioxidant enzymes. 
GPx4 is responsible for the majority of lipid hydroperoxidase activity in mammalian cells 
at physiological pH [166]. It is interesting that mRNA for this gene increased in 
correlation with increases in 8-isoprostanes and oxidized lipids. 
In contrast to GPx4, level of Prdx6 decreased in KO mice at 2 months. Prdx6, has both 
lipid hydroperoxidase activity and phospholipase A2 activity, but the hydroperoxidase 
activity is 40-fold greater than its phospholipase activity at physiological pH [169-171]. 
Other studies revealed that Prdx6 is regulated by ERK and p38 pathways and these 
pathways are also implicated in iPLA2 regulation as demonstrated by an upregulation of 
both iPLA2 and Prdx6 with PMA treatment and, conversely, knockdown of iPLA2 
increased MAPK activation [181-182]. Our data suggests that common signaling 
pathways may exist between Prdx6 and iPLA2y and these findings should be further 
explored. 
These data showing genetic ablation of iPLA2y does not effect GR1 mRNA expression 
but alters the expression of GPx4 and Prdx6, supports the hypothesis that iPLA2¥ ablation 
induced lipid peroxidation and not an overall increase in redox cycling under these 
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conditions. Similarly, Yoda et al. reported increased MDA content and the induction of 
antioxidant enzymes in the skeletal muscle of mice genetically ablated of iPLA2y. 
These data reveal that genetic ablation of iPLA2y results in oxidant injury (lipid 
peroxidation, oxidative DNA damage) that coincides with a disruption of mitochondrial 
respiratory protein expression and loss of lipid homeostasis in the kidney. Additionally, 
these studies reveal that genetic ablation of iPLA2Y induces compensatory responses to 
oxidative stress, such as increased mtDNA, modulation of mitochondrial respiratory 
proteins, and upregulation of oxidant stress response pathways. Despite the increase in 
oxidative stress in the kidney, iPLA2y ablation-associated oxidant injury does not appear 
to be great enough to overcome kidney reserve and regenerative capacity as iPLA2Y 
ablated mice do not exhibit greater loss of kidney function at 13 months of age. It should 
be pointed out that further studies are needed in older mice to fully assess the effect of 
iPLA2y ablation on aging and oxidative stress. Interestingly, Mancuso et al. showed that 
ablation of iPLA2y alone was not sufficient to cause cardiac dysfunction, but a 
subsequent insult, transverse aortic constriction, revealed cardiac dysfunction in iPLA2y 
KO mice [136]. Similarly, age-associated changes in kidney structure and function are 
not always sufficient to cause kidney dysfunction, but it is believed that these changes 
make the kidney more vulnerable to subsequent insults (ie. ischemialreperfusion-, drug-, 
and toxicant injury) [183-184]. A subsequent kidney insult, such as ischemialreperfusion 




Conclusions and Future Directions 
In conclusion, acute kidney injury and chronic kidney disease are becoming more 
prevalent and have high morbidity and mortality that have been unchanged for many 
years. Current therapeutics targeted towards preventing or treating kidney injury and 
disease have been unsuccessful. Calcium-independent phospholipase A2y (iPLA2Y) is one 
of seven Ca2+ -independent PLA2 enzymes and represents a potential therapeutic target in 
kidney disease [81]. Our studies in renal cells showed that iPLA2y has a unique 
subcellular localization in that its expression and activity were found in both the 
endoplasmic reticulum (ER) and the mitochondria, while iPLA2~ activity was not present 
[68, 97-98]. We also determined that iPLA2y has divergent roles in cell injury and death, 
which may be explained by unique roles and functions within subcellular compartments 
[81]. Specifically, iPLA2Y is protective during oxidant-induced necrotic cell death, but 
seems to mediate apoptosis-induced cell death. Additionally, iPLA2Y in mitochondria 
plays a protective role during oxidant-induced lipid peroxidation and subsequent 
mitochondrial swelling, but seems to mediate Ca2+ induced mitochondrial swelling via 
arachidonic acid signaling. Unfortunately, lack of organelle specific inhibitors of iPLA2y 
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limited studies to isolated organelles and studies in RPTC were not able to distinguish the 
respective contributions of ER- and mitochondrial- iPLA2¥. However, recent studies in 
our laboratory using iPLA2¥-specific shRNA to decrease iPLA2¥ activity and expression 
in RPTC decreased ER- iPLA2¥ prior to mitochondrial- iPLA2¥. These studies confirmed 
role of iPLA2¥ in preventing lipid peroxidation and preserving mitochondrial function 
and viability under basal conditions [116]. More importantly, while the loss of 
mitochondrial iPLA2¥ was correlated with decreased mitochondrial uncoupled 
respiration, these studies pointed to ER - iPLA2Y in the lipid peroxidation 
repair/prevention pathway because knockdown of ER- iPLA2¥, and not mitochondrial-
iPLA2Y, was correlated with increased lipid peroxidation. However, no studies have 
elucidated the role of iPLA2y in the ER nor has the mechanism by which iPLA2y 
preserves phospholipid homeostasis been determined. The goals of these studies were to 
elucidate the role of ER- iPLA2Y in oxidant-induced ER lipid peroxidation, loss of lipid 
homeostasis, Ca2+ release and renal cell death. 
Sarcoplasmic/endoplasmic reticulum (ER) Ca2+ is the most abundant store of intracellular 
Ca2+, and its release is an important trigger of physiological and pathophysiological 
processes, including signaling and cell death pathways. Previous work in our laboratory 
revealed the importance of ER Ca2+ in toxicant-induced necrotic renal proximal tubular 
cell (RPTC) death. The studies presented here focus on RPTC necrotic cell death. In 
order to ultimately elucidate the role of iPLA2¥ in toxicant-induced ER Ca
2+ release and 
necrotic RPTC death, we needed to develop an assay to visualize ER Ca2+ release in 
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RPTC. Prior methods of monitoring ER Ca2+ required extensive loading techniques, 
disruption of cell membranes, and/or genetic manipulation of cells to express Ca2+ 
sensitive proteins. These techniques were not ideal because of our use of primary cells 
and employing these methods would likely further disrupt RPTC physiology. The 
purpose of this study (Chapter 2) was to evaluate the use of confocal microscopy and 
Fluo5F, a low affinity Ca2+ indicator, to directly monitor changes in RPTC ER Ca2+. 
Flu05F staining reflected ER Ca2+, resolved ER structure, and showed no colocalization 
with tetramethyl rhodamine methyl ester (TMRM), a marker of mitochondrial membrane 
potential. These data provide evidence that confocal microscopy and Flu05F are useful 
and effective tools for directly monitoring ER Ca2+ in intact cells. These studies 
furthered our understanding of RPTC ER Ca2+ stores and Ca2+ release-induced 
mitochondrial depolarization. This assay would later be used to elucidate the role of 
iPLA2y in oxidant-induced ER Ca
2
+ release in RPTC. 
Oxidant-induced lipid peroxidation and cell death are major components of ischemia-
reperfusion and toxicant injury. Our present studies reveal the role of ER - iPLA2Y in 
oxidant-induced ER lipid peroxidation, Ca2+ release, and cell death in isolated ER 
(micro somes) and RPTC (Chapter 3). We developed assays using cis-parinaric acid, a 
lipid moiety that loses fluorescence with oxidation, and Fluo-4, a Ca2+ -sensitive probe, to 
monitor microsomal lipid peroxidation and Ca2+ release, respectively. Traditional 
methods of measuring microsomal Ca2+ release utilized radioactive 45Ca and isolation 
filters. These methods were cumbersome, required relatively large amounts of 
microsomes, and lacked the ability to continuously measure Ca2+ release in real-time. 
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The use of cis-parinaric acid and fluo-4 allowed for the measurement of both lipid 
peroxidation and Ca2+ release in real-time under similar conditions. Oxidant, tert-butyl 
hydroperoxide (TBHP), caused ER lipid peroxidation and Ca2+ release in isolated rabbit 
kidney cortex microsomes. ER- iPLA2y inhibition, using bromoenol lactone (BEL), 
potentiated both oxidant-induced ER lipid peroxidation and Ca2+ release. These finding 
correlated with our studies in mitochondria showing that mitochondrial- iPLA2Y 
prevented oxidant-induced lipid peroxidation and mitochondrial swelling. Additionally, 
the initiation of lipid peroxidation occurred prior to microsomal Ca2+ release and these 
studies excluded the role mitochondria and mitochondrial-iPLA2Y. Together, these 
findings provide evidence that ER Ca2+ release is the result of lipid peroxidation- induced 
membrane disruption and not signaling. 
PLA2 enzymes catalyze the hydrolysis of fatty acids at. the sn-2 position of 
glycerophospholipids resulting in the production of a free fatty acid and a 
lysophospholipid. Fatty acids at the sn-2 position tend to be unsaturated and are therefore 
more vulnerable to oxidative stress. PLA2s were hypothesized to play a role in 
membrane remodeling/repair by preferentially cleaving damaged (oxidized) fatty acids 
from the membrane and allowing the re-esterification of native (non-oxidized) fatty acids 
and lysophospholipid. We utilized electrospray ionization-mass spectrometry (ESI-MS) 
to investigate the role of ER- iPLA2Y in oxidant-induced ER fatty acid release. Fatty acid 
assessment revealed that ER- iPLA2Y mediates the TBHP-induced release of arachidonic 
acid (20:4), linoleic acid (18:2), and their oxidized forms (18:2-0H, 18:2-00H, 20:4-
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OH, 20:4-00H, 20:4-(OH)3). These findings provide evidence that ER- iPLA2Y prevents 
ER Ca2+ release by mediating the release of unsaturated and/or oxidized fatty acids and 
thereby maintaining ER membrane integrity. Additionally, these findings, to our 
knowledge, are the first to connect PLA2 activity, its role in membrane remodeling/repair, 
and the pathophysiological consequences of the loss of PLA2 activity with respect to 
membrane repair. 
We then demonstrated in intact cells that iPLA2y inhibition also accelerated oxidant-
induced ER Ca2+ release in RPTC using the methods developed in Chapter 2. To connect 
oxidant-induced ER Ca2+ release with necrotic cell death, we carried out studies using 
flow cytometry. Depletion of RPTC ER Ca2+ stores with thapsigargin, an ER Ca2+ pump 
inhibitor, prior to TBHP exposure reduced necrotic cell death and blocked the 
potentiation of TBHP-induced necrotic cell death by BEL. These data provide strong 
evidence that ER- iPLA2y protects renal cells from oxidant-induced necrotic cell death by 
preventing ER Ca2+ release. These findings, along with the studies in microsomes, 
provide evidence that ER- iPLA2Y releases unsaturated and/or oxidized fatty acids during 
oxidant stress to preserve ER membrane integrity and prevent ER Ca2+ release, thereby 
preventing necrotic cell death. These studies, to our knowledge, are the first elucidate the 
mechanism by which ER- iPLA2Y is cytoprotective during oxidative stress. 
We tested this hypothesis in vivo using mice genetically ablated of iPLA2y (KO mice) 
and investigated its role in age-related renal oxidant injury. To determine oxidant injury, 
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we measured urInary 8-isoprostanes and 8-hydroxy-2' -deoxyguanosine (8-0HdG), 
biomarkers of lipid peroxidation and oxidative DNA damage, respectively. Both 8-
OHdG and 8-isoprostanes increased in aged KO mice. These date provide evidence that 
genetic ablation of iPLA2y results in increased oxidative stress in KO animals. However, 
because these markers in urine reflect global changes in oxidant status, further studies 
were required to elucidate the role iPLA2y in the kidney, specifically. 
Interestingly, urInary lipidomic analysis in KO animals uSIng ESI-MS demonstrated 
decreases in phospholipid species 38:6, 38:5 and 37:5 phosphatidylcholine and increases 
in 6-10 carbon fatty acids, with methyl or keto additions. These findings correlated with 
our studies in microsomes (Chapter 3) demonstrating iPLA2y is cytoprotective by 
preventing lipid peroxidation and preserving membrane homeostasis. Previous studies 
using shRNA to knockdown iPLA2Y in RPTC demonstrated a similar build-up of 
phosphatidylcholine containing phospholipids. These findings provide strong evidence 
that the mechanism by which iPLA2Y is protective in vitro is physiologically relevant in 
vivo. 
To further investigate the role of iPLA2Y in kidney oxidant stress in vivo, we measured 
kidney specific oxidant injury. Our findings that 13 month KO mouse kidney cortex 
exhibited higher lipid peroxidation and 8-0HdG staining confirmed kidney specific 
oxidant injury. These findings were correlated with changes in renal mitochondrial 
respiratory proteins ATP Synthase B, NDUFB8, and COX-I, increases in mitochondrial 
DNA copy number, and increases in GPx4 mRNA expression in KO mice. Increased 
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mitochondrial DNA copy number is thought to be a compensatory response to oxidative 
stress to maintain mitochondrial number and function and GPx4 is an antioxidant enzyme 
that contains lipid hydroperoxidase activity and is believed to be a component of the 
membrane remodeling/repair pathway. Interestingly, genetic ablation of iPLA2¥ did not 
result in loss of kidney function. It is likely that iPLA2¥ ablation, as expected, induced 
oxidant injury, but resulted in a compensatory response to maintain tissue viability as 
evidenced by mitochondrial changes and increases in oxidant stress response pathways. 
Collectively, these data support our hypothesis that ER- iPLA2y protects renal cells from 
oxidant-induced necrotic cell death by preventing ER lipid peroxidation, preserving ER 
membrane integrity, and blocking ER Ca2+ release and loss of Ca2+ homeostasis. These 
studies revealed ER- iPLA2¥ preferentially cleaves unsaturated and/or oxidized fatty 
acids under oxidant stress and provides the mechanism by which it is protective. We also 
confirmed iPLA2¥ plays a similar and crucial role in oxidative stress in vivo. Together, 
these studies have elucidated the role of iPLA2¥ in oxidant-induced renal cell death, 
revealed the mechanism by which ER- iPLA2¥ is cytoprotective, and has furthered our 
understanding of kidney physiology and pathophysiology in the setting of aging and 
oxidant injury. iPLA2y represents a potential therapeutic target to prevent acute kidney 
injury in patients at high risk or hasten recovery of kidney function following AKI. 
Further understanding of the role of iPLA2y in chronic kidney disease may elucidate 




The studies presented here focus on the role of iPLA2y in oxidant-induced necrotic cell 
death and have uncovered several questions that require further investigation. 
Additionally, the role of iPLA2y in apoptosis-induced renal cell death or its role in cell 
signaling was not investigated within the scope of these studies. Potential investigations 
will be presented here. 
Our previous studies demonstrated iPLA2¥ mediates cisplatin-induced renal apoptotic cell 
death and studies in mitochondria demonstrated iPLA2y mediates Ca
2
+ - induced 
mitochondrial swelling through an arachidonic acid-dependent initiation of mitochondrial 
pore transition. Because apoptosis is thought to be a major component of age-related loss 
of kidney function and thought to playa role in the progression of chronic kidney disease 
to end-stage renal failure, elucidating the role of iPLA2Y in apoptosis-induced cell death 
may uncover potential therapeutics in renal injury. The assays developed and 
experimental methods utilized during the course of these experiments may be used to 
further investigate the role of iPLA2y in apoptosis. Specifically, renal cell imaging using 
confocal microscopy to monitor mitochondrial membrane potential and Ca2+ dynamics 
may help to elucidate the role of iPLA2Y in cisplatin-induced renal cell apoptosis. 
iPLA2¥ regulation was not investigated during the course of these experiments. Our 
previous studies demonstrate phorbol 12-myristate 13-acetate (PMA), a protein kinase C 
(PKC) activator, increased ER-iPLA2¥ activity and potentiated cisplatin-induced 
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apoptosis [112]. Interestingly, RPTC exposed to PMA activates only ER-iPLA2y and not 
mitochondrial iPLA2y (Figure 5-1). These findings suggest that ER-iPLA2y activity may 
be more closely regulated by phosphorylation status. Furthermore, exposure of RPTC to 
PKCE VI-2 specifically decreased ER-iPLA2y activity and prevented PMA-induced 
activation of ER-iPLA2y. Together these findings suggest that ER-iPLA2y, and not 
mitochondrial iPLA2y, is regulated by PKCE-induced phosphorylation and ER-iPLA2y 
activity may be specifically manipulated while mitochondrial- iPLA2y remains 
unchanged. 
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Figure 5-1. Effect of PMA and PKCE inhibitor on ER and mitochondrial iPLA2y 
activity in RPTC. RPTC were exposed to the PKCE VI-2 inhibitor (Inh, 20 J.lM) for 1 
hr and 24 hr or PMA (100 nM for 30 minutes) in the presence and absence of the PKCE 
VI-2 inhibitor (1 hour pretreatment). ER and mitochondrial fractions were isolated from 
RPTC and iPLA2 activity measured using synthetic plasmenylcholine (16:0, eH] 18: 1). 
Data are presented as the mean + SEM. Means with different superscripts are 
significantly different from each other, p < 0.05, n=4. 
It has been proposed that iPLA2y activity and function is regulated by phophorylation and 
differential expression of splice variants. Analysis of the amino acid sequence of iPLA2y 
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showed that there are many potential serine, threonine and tyrosine phosphorylation sites 
[96, 185]. However, the phosphorylation of specific amino acids on iPLA2y has not been 
has not been investigated and little is known of the kinases and phosphatases involved. 
Experiments directed at elucidating the mechanism by which iPLA2y is regulated by 
phosphorylaton need to be addressed. 
Our studies in microsomes presented in Chapter 3 revealed several interesting findings 
using ESI-MS. The goal of these studies were to elucidate the mechanism by which ER-
iPLA2y prevents lipid peroxidation, and these studies demonstrated ER-iPLA2Y mediates 
the release of unsaturated and/or oxidized fatty acids during oxidative stress. However, 
these studies also revealed that inhibition of ER-iPLA2Y by BEL increased the release of 
a lipid species at M/z 345. This species may represent 1) a signaling molecule involved in 
the initiation of ER Ca2+ release, 2) the build-up of a lipid substrate specifically acted 
upon by ER-iPLA2yand/or 3) the byproduct of ER membrane disruption. Further 
investigation of this lipid moiety may reveal the long sought after 
iPLA2Y substrate/signaling molecule (Figure 5-2). 
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Figure 5-2. Inhibition of iPLA2Y induces the release of lipid (m/z 345) from 
microsomes. Released lipids were separated from microsomes using differential 
centrifugation, extracted by Bligh Dyer method, injected directly into ESI-Mass 
Spectrometer, and analyzed in negative mode. Microsomes were pretreated for 20 min 
with BEL or diluent, treated for 30 min with 200 ~M TBHP, and reaction was stopped 
and analyzed by ESI-MS. 
Our studies in mice genetically ablated of iPLA2Y (Chapter 4) suggest ablation-associated 
oxidant injury is not great enough to overcome kidney reserve and regenerative capacity 
and iPLA2y ablated mice do not exhibit greater loss of kidney function at 13 months of 
age. Interestingly, Mancuso et al. showed that ablation of iPLA2y alone was not sufficient 
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to cause cardiac dysfunction, but a subsequent insult, transverse aortic constriction, 
revealed cardiac dysfunction in iPLA2y KO mice [136]. Similarly, age-associated 
changes in kidney structure and function are not always sufficient to cause kidney 
dysfunction, but it is believed that these changes make the kidney more vulnerable to 
subsequent insults (ie. ischemialreperfusion-, drug-, and toxicant injury) [183-184]. A 
subsequent kidney insult, such as ischemialreperfusion or toxicant injury, may reveal 
kidney dysfunction in KO mice. We have developed a model of ischemiaireperfusion 
(Figure 5-3) and toxicant injury (Figure 5-4) that may be used to reveal kidney 
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Figure 5-3. Kidney dysfunction after ischemia-reperfusion injury. Serum creatinine 
levels were significantly elevated 24 h after reperfusion, and then slowly decreased 
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between 24 hand 144 h without returning to normal levels. Different superscripts above 
data points are significantly different from one another (P < 0.05). From Funk and 
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Figure 5-4. Renal dysfunction after glycerol-induced myoglobinuria. (A) Serum 
creatinine was maximal 24 h after injection, and partially recovered between 24 h and 
144 h after injury without returning to normal levels. (B) Urine creatinine was reduced 48 
h after injury and remained decreased at 144 h. Urine glucose (C) and NGAL (D) were 
elevated 48 h after glycerol injection and remained elevated at 144 h. Different 
superscripts above data points are significantly different from one another (P < 0.05). 
From Funk and Schnellmann, 2011 [19]. 
Additional studies are need in KO mice to further elucidate the role of iPLA2Y in oxidant 
injury and loss of renal function in vivo. Studies in animals older than 13 months may 
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reveal an earlier onset of age-associated loss of kidney function in iPLA2Y ablated mice. 
Additionally, older KO animals should be subjected to our model of 
ischemialreperfusion-induced kidney injury and may reveal iPLA2Y ablated animals are 
more vulnerable to a subsequent injury. There are several studies of iPLA2Y that require 
further investigation and may further our understanding of the role iPLA2y in renal 
physiology and pathophysiology, responses of renal cells to oxidant injury, and the 
molecular and physiological changes within the aging kidney. 
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